RASA1 (p120GAP): A Comprehensive Review of Ras GTPase-Activating Protein 1

Introduction and Summary

RASA1 (Ras GTPase-activating protein 1), also known as p120GAP, RasGAP, or p120-RasGAP, is a 120 kDa cytoplasmic protein that serves as a critical negative regulator of Ras signaling. The protein was the first GTPase-activating protein discovered for the Ras family of small GTPases, with its identification by Trahey and McCormick in 1987 representing a fundamental advance in understanding how Ras signaling is controlled in cells [trahey-1987-gap-discovery-abstract]. RASA1 functions by dramatically accelerating the intrinsic GTPase activity of Ras proteins, converting them from the active GTP-bound state to the inactive GDP-bound state and thereby terminating Ras-mediated mitogenic signaling [scheffzek-2019-rasgap-review-summary].

The primary enzymatic function of RASA1 is to catalyze GTP hydrolysis on Ras proteins through a mechanism involving an "arginine finger" that stabilizes the transition state of the hydrolysis reaction [scheffzek-1997-ras-rasgap-complex-summary]. This catalytic activity enhances the rate of GTP hydrolysis by approximately 10^5-fold compared to the intrinsic rate, making it an extraordinarily efficient regulator of Ras activity [scheffzek-2019-rasgap-review-summary]. Beyond its catalytic function, RASA1 serves as a multifunctional scaffold protein that participates in signal transduction through its N-terminal protein-protein interaction domains, connecting receptor tyrosine kinase signaling to downstream effectors [pamonsinlapatham-2009-rasgap-multiinteracting-summary].

RASA1 is ubiquitously expressed and essential for embryonic development, as demonstrated by the embryonic lethality of Rasa1 knockout mice at embryonic day 10.5 due to severe vascular and neuronal defects [henkemeyer-1995-rasgap-knockout-abstract]. In humans, germline loss-of-function mutations in RASA1 cause capillary malformation-arteriovenous malformation syndrome (CM-AVM1), a vascular disorder characterized by multiple capillary malformations and, in some cases, fast-flow arteriovenous malformations [chen-2023-ephb4-rasa1-summary]. These genetic findings have provided crucial insights into the biological importance of RASA1-mediated Ras regulation in vascular development and maintenance.

Domain Architecture and Protein Structure

RASA1 is a modular protein comprising multiple functional domains that enable both its catalytic and scaffolding functions. From the N-terminus to the C-terminus, the protein contains: two SH2 (Src homology 2) domains separated by a single SH3 (Src homology 3) domain, followed by a pleckstrin homology (PH) domain, a C2 domain, and finally the C-terminal GAP catalytic module [scheffzek-2019-rasgap-review-summary]. This domain organization positions RASA1 uniquely among the ten mammalian RasGAPs, as it is the only family member to contain SH2 domains [stiegler-2022-sh2-tandem-summary].

The GAP catalytic module itself consists of two structural domains: the central catalytic domain (GAPc) and an extra domain (GAPex). The minimal catalytic fragment, termed GAP-334 (residues 714-1047), was the first GTPase-activating protein to have its structure determined by X-ray crystallography [scheffzek-1996-gap334-structure-summary]. This structure revealed an elongated, exclusively helical protein representing a novel protein fold at the time of its discovery in 1996. The GAPex domain, while structurally conserved, is dispensable for catalytic activity, with all residues essential for GAP function residing within the GAPc domain [scheffzek-2019-rasgap-review-summary].

The N-terminal SH2-SH3-SH2 cassette enables RASA1 to interact with phosphotyrosine-containing proteins, including activated receptor tyrosine kinases such as PDGFR (platelet-derived growth factor receptor), EGFR (epidermal growth factor receptor), and EphB receptors [chen-2023-ephb4-rasa1-summary]. Structural studies have revealed that the two SH2 domains can engage dual phosphotyrosine residues in a single binding partner through a "bidentate" binding mode, achieving remarkably tight binding affinities of approximately 10 nM—a 15-30 fold enhancement compared to single SH2 domain engagement [stiegler-2022-sh2-tandem-summary]. Notably, the C-terminal SH2 domain employs an unusual "FLVR-unique" phosphotyrosine binding mechanism in which the conserved arginine residue makes an intramolecular salt bridge rather than directly coordinating the phosphotyrosine [stiegler-2022-sh2-tandem-summary].

The PH domain of RASA1 contributes to membrane localization through its ability to bind phosphoinositide lipids, particularly phosphatidylinositol 4,5-bisphosphate (PIP2). PH domains function by recruiting their host proteins to membranes enriched in specific phosphoinositides, thereby positioning RASA1 in proximity to membrane-bound Ras proteins. The C2 domain, located immediately proximal to the GAP catalytic module, was initially presumed to serve primarily as a calcium-dependent phospholipid-binding module for membrane targeting. However, recent research has revealed an unexpected direct role for the C2 domain in augmenting catalytic activity through interaction with the Ras allosteric lobe, with residue R707 at the center of an evolutionarily conserved surface critical for this function [scheffzek-2019-rasgap-review-summary].

Enzymatic Mechanism and Catalysis

The primary biochemical function of RASA1 is to accelerate GTP hydrolysis by Ras proteins through a well-characterized mechanism involving transition state stabilization. The discovery of this activity by Trahey and McCormick in 1987 demonstrated that a cytoplasmic protein could stimulate the GTPase activity of normal N-Ras p21 by more than 200-fold in vitro [trahey-1987-gap-discovery-abstract]. Subsequent structural and biochemical studies have revealed that the rate enhancement achieved by RasGAPs can reach 10^5-fold, converting the slow intrinsic hydrolysis rate of Ras into a rapid switch mechanism suitable for controlling cellular signaling [scheffzek-2019-rasgap-review-summary].

The catalytic mechanism centers on the "arginine finger" provided by the GAP domain. In RASA1, this essential residue is Arg789, which inserts into the active site of Ras-GTP and contacts the β/γ phosphate region of the bound nucleotide [scheffzek-1997-ras-rasgap-complex-summary]. The importance of this residue is demonstrated by mutagenesis studies showing that even conservative substitution of arginine to lysine reduces GAP activity by three orders of magnitude [scheffzek-2019-rasgap-review-summary]. The arginine finger serves dual roles: it helps position the nucleophilic water molecule for attack on the γ-phosphate, and it stabilizes the developing negative charge during the transition state of phosphoryl transfer.

A seminal contribution to understanding this mechanism came from the crystal structure of the Ras-RasGAP complex in the presence of aluminum fluoride, which mimics the transition state of the GTP hydrolysis reaction [scheffzek-1997-ras-rasgap-complex-summary]. This structure, solved at 2.5 Å resolution, revealed that aluminum fluoride forms a pentagonal bipyramidal geometry with the fluorides forming the trigonal base and two apical oxygen ligands. The arginine finger from RASA1 contacts one of the fluorides, demonstrating how the GAP neutralizes developing charges on the γ-phosphate during the phosphoryl transfer reaction.

The structure also explains why oncogenic Ras mutations at positions G12, G13, and Q61 are insensitive to GAP-mediated stimulation. Glutamine 61 is essential for proper positioning of the nucleophilic water molecule, and mutations at this position virtually eliminate GAP sensitivity [scheffzek-1997-ras-rasgap-complex-summary]. Glycine 12 is positioned near both the arginine finger and Gln61 in the active site; substitution of larger residues at this position sterically interferes with proper arginine finger insertion and prevents formation of the catalytically competent complex. This structural understanding explains the fundamental observation of Trahey and McCormick that the GAP activity does not affect oncogenic Ras mutants [trahey-1987-gap-discovery-abstract].

Substrate Specificity

RASA1 functions as a GAP for classical Ras isoforms (H-Ras, K-Ras, and N-Ras) without significant preference among these three proteins. The catalytic domains of RASA1 and neurofibromin (NF1), the two best-characterized RasGAPs, interact with H-Ras, N-Ras, and K-Ras with similar efficiency [scheffzek-2019-rasgap-review-summary]. This broad specificity toward classical Ras proteins positions RASA1 as a general negative regulator of Ras signaling rather than an isoform-specific modulator.

Interestingly, RASA1 displays differential activity toward R-Ras compared to classical Ras proteins. Kinetic measurements have shown that RASA1 actually has higher affinity for R-Ras (EC50 ~3.9 nM) compared to H-Ras (EC50 ~23 nM), representing approximately 6-fold selectivity toward R-Ras [scheffzek-2019-rasgap-review-summary]. This contrasts with GAP1m, another RasGAP, which preferentially stimulates classical Ras GTPase activity over R-Ras. The biological significance of this selectivity pattern remains an area of ongoing investigation.

Comparison with neurofibromin reveals important differences in Ras binding properties despite similar catalytic mechanisms. The affinity of neurofibromin for Ras-GTP is 50- to 100-fold higher than that of RASA1, while the kinetics of association and dissociation are much faster for RASA1 [scheffzek-2019-rasgap-review-summary]. This suggests that neurofibromin may function as a more persistent Ras regulator once bound, while RASA1 rapidly cycles on and off Ras-GTP in a manner more suited to dynamic signaling regulation. Despite these kinetic differences, both proteins utilize the same fundamental arginine finger mechanism for catalysis.

Subcellular Localization and Membrane Recruitment

RASA1 is predominantly a cytosolic protein that undergoes regulated recruitment to cellular membranes where it can access its substrate, membrane-bound Ras-GTP. Multiple mechanisms contribute to RASA1 membrane localization, reflecting the importance of spatial control for its function as a Ras regulator. According to the Human Protein Atlas, RASA1 shows primary localization to vesicles and the basal body, with additional presence in the cytosol [scheffzek-2019-rasgap-review-summary].

Growth factor stimulation triggers translocation of RASA1 from the cytoplasm to the plasma membrane. This recruitment is facilitated by the SH2 and SH3 protein interaction domains, which mediate binding to activated receptor tyrosine kinases and their associated signaling complexes [chen-2023-ephb4-rasa1-summary]. The SH2 domains recognize specific phosphotyrosine motifs on receptors such as PDGFR, EGFR, and EphB4. In the case of EphB4, RASA1 binds through SH2 domain recognition of a pair of autophosphorylated tyrosine residues in the receptor juxtamembrane region [chen-2023-ephb4-rasa1-summary].

Beyond receptor-mediated recruitment, RASA1 membrane targeting involves the adaptor protein Annexin A6. This calcium-dependent membrane-binding protein interacts constitutively with RASA1 in the cytosol and promotes its Ca2+-dependent recruitment to the plasma membrane upon stimulation [grewal-2005-annexin-a6-abstract]. Annexin A6 acts as a scaffold that assembles RASA1-Ras complexes at the membrane, thereby facilitating Ras inactivation. Expression of Annexin A6 reduces EGF-induced Ras and ERK activation, while suppression of Annexin A6 enhances Ras signaling, demonstrating the physiological importance of this mechanism [grewal-2005-annexin-a6-abstract].

The PH domain provides direct lipid-binding capacity through recognition of phosphoinositides such as PIP2. Additionally, the C2 domain may contribute to membrane association, although recent evidence suggests its primary role may be in direct catalytic enhancement rather than membrane targeting [scheffzek-2019-rasgap-review-summary]. An alternative model proposes that RASA1 is targeted to Ras-GTP through recognition of membrane lipids generated during EphB4 signaling rather than solely through direct protein-protein interaction [chen-2023-ephb4-rasa1-summary].

Role in Ras-MAPK Signaling

RASA1 functions as a critical negative regulator of the Ras-MAPK (mitogen-activated protein kinase) signaling pathway, one of the most important signal transduction cascades controlling cell proliferation, differentiation, and survival. In this pathway, activated Ras-GTP binds to and activates the serine-threonine kinase RAF, which phosphorylates MEK1/2, which in turn phosphorylates and activates ERK (extracellular signal-regulated kinase) [chen-2023-ephb4-rasa1-summary]. By converting Ras-GTP to Ras-GDP, RASA1 terminates signaling through this entire cascade.

A particularly well-characterized context for RASA1 function is the EPHB4-RASA1 signaling axis in endothelial cells. The receptor tyrosine kinase EphB4 communicates with RASA1 to inhibit Ras activation in endothelial cells, with knockdown of RASA1 in human umbilical vein endothelial cells blocking EphB4's ability to inhibit the Ras-MAPK pathway [chen-2023-ephb4-rasa1-summary]. This functional relationship positions EPHB4 as an upstream regulator that dampens Ras-MAPK signaling through RASA1-dependent mechanisms, rather than activating downstream signaling like conventional growth factor receptors.

The importance of this regulatory relationship is demonstrated by the consequences of EPHB4 or RASA1 deficiency. Loss of either protein results in greatly augmented activation of ERK MAPK in endothelial cells during developmental angiogenesis [chen-2023-ephb4-rasa1-summary]. During lymphangiogenesis, EPHB4 and RASA1 cooperate to limit the duration of Ras-MAPK signaling induced by VEGF-C binding to VEGFR3. In the absence of either protein, prolonged Ras-MAPK signaling leads to lymphatic endothelial cell apoptosis [chen-2023-ephb4-rasa1-summary].

RASA1 also participates in crosstalk between Ras and Rho GTPase signaling pathways through its interaction with p190RhoGAP. The tandem SH2 domains of RASA1 engage dual phosphotyrosine residues on p190RhoGAP with high affinity, potentially coordinating the activities of these two major small GTPase families [stiegler-2022-sh2-tandem-summary]. This bidentate binding mechanism may function as a highly selective signaling gate, ensuring that Ras-Rho pathway coordination occurs only under specific phosphorylation conditions.

Role in Apoptosis Regulation

Beyond its canonical function as a Ras-GTPase activating protein, RASA1 plays an unexpected role in regulating cell survival and apoptosis through a mechanism involving caspase-mediated cleavage. This function positions RASA1 as a stress sensor that can modulate cell fate decisions depending on the intensity of apoptotic stimuli.

During the early phases of apoptosis, RASA1 is proteolytically cleaved by caspase-3 at two distinct sites [wen-1998-rasgap-cleavage-abstract]. Initial cleavage at position 455 generates an N-terminal fragment (fragment N, amino acids 1-455) and a C-terminal fragment (fragment C, amino acids 456-1047). Under conditions of high caspase activity, fragment N is further cleaved at position 157, generating smaller fragments [yang-2001-caspase-rasgap-summary]. Remarkably, the biological outcomes of this cleavage depend critically on the extent of processing.

At low levels of caspase-3 activity, such as might occur during mild cellular stress, partial cleavage of RASA1 generates an antiapoptotic response [yang-2001-caspase-rasgap-summary]. Fragment N, produced by initial cleavage at position 455, activates the prosurvival Akt kinase in a Ras-dependent manner, preventing further amplification of caspase activity and allowing cells to recover from transient stress. This partial cleavage mechanism is essential for cell survival under stress conditions, as cells expressing an uncleavable RASA1 mutant cannot activate Akt, cannot prevent amplification of caspase-3 activity, and eventually undergo apoptosis even in response to mild stress [yang-2001-caspase-rasgap-summary].

In contrast, at high levels of caspase activity, further cleavage at position 157 abolishes the antiapoptotic capacity of fragment N, and the resulting fragments become proapoptotic [yang-2001-caspase-rasgap-summary]. Fragment C expressed alone can induce apoptosis, although this effect is blocked when fragment N is co-expressed. This elegant "apoptostat" mechanism allows RASA1 to function as a sensor of caspase activity levels, promoting survival under mild stress but permitting apoptosis when cellular damage is severe.

Additional complexity in this pathway emerged from studies showing that fragment N also functions as an NF-κB inhibitor by promoting nuclear export of NF-κB. Cells unable to generate fragment N display increased NF-κB activation upon stress, and knock-in mice expressing uncleavable RASA1 show exaggerated NF-κB activation when their epidermis is treated with inflammatory stimuli. Thus, RASA1 cleavage serves to modulate multiple stress-responsive signaling pathways beyond its primary role in Ras regulation.

Physiological Functions and Disease Associations

The essential role of RASA1 in mammalian development was established by gene targeting studies in mice. Homozygous deletion of Rasa1 results in embryonic lethality at approximately embryonic day 10.5, with affected embryos displaying severe defects in both yolk sac and embryonic vascular systems [henkemeyer-1995-rasgap-knockout-abstract]. The vascular abnormalities reflect impaired ability of endothelial cells to organize into properly structured vascular networks. In addition to vascular phenotypes, Rasa1 null embryos exhibit extensive neuronal apoptosis, indicating that RASA1-mediated Ras regulation is important for neuronal survival during development [henkemeyer-1995-rasgap-knockout-abstract].

Double mutant studies combining Rasa1 and Nf1 (neurofibromin) deficiency demonstrate amplified phenotypic abnormalities, indicating that these two RasGAPs act together to regulate Ras activity during embryonic development [henkemeyer-1995-rasgap-knockout-abstract]. This genetic interaction suggests that while there may be some functional redundancy between RasGAPs, each contributes uniquely to maintaining appropriate levels of Ras signaling in specific developmental contexts.

In humans, germline heterozygous loss-of-function mutations in RASA1 cause capillary malformation-arteriovenous malformation syndrome type 1 (CM-AVM1), which accounts for approximately 70% of CM-AVM cases [chen-2023-ephb4-rasa1-summary]. The remaining 30% (CM-AVM2) are caused by mutations in EPHB4, the upstream receptor that signals through RASA1. The clinical features are indistinguishable between these two genetic forms, consistent with their function in a shared signaling pathway. CM-AVM is characterized by multiple small capillary malformations, typically 1-2 cm in diameter and often surrounded by a pale halo, that appear on the face and limbs and increase in number with age. Some affected individuals also develop fast-flow arteriovenous malformations (AVMs) or arteriovenous fistulas in the skin, muscle, bone, spine, or brain.

Parkes Weber syndrome represents a related but more severe manifestation within the RASA1 mutation spectrum. This condition is characterized by multiple micro-arteriovenous fistulas associated with segmental overgrowth of soft tissue and skeletal components affecting a limb. Originally considered a sporadic, non-genetic condition, Parkes Weber syndrome is now recognized as part of the CM-AVM spectrum caused by RASA1 mutations. Germline inactivating variants in RASA1 are detected in 50-85% of individuals with Parkes Weber syndrome. The focal nature and variable expressivity of vascular lesions in these conditions supports a two-hit model, wherein complete loss of RASA1 function through biallelic inactivation (the inherited germline mutation plus a somatic "second hit") is required for lesion development. This model has been confirmed by identification of somatic RASA1 mutations in lesional tissue from affected patients. Notably, both germline and postzygotic (mosaic) RASA1 mutations can lead to CM-AVM and Parkes Weber syndrome phenotypes.

Most pathogenic RASA1 mutations are nonsense mutations, splice site substitutions, or frameshift mutations that result in premature stop codons and predicted loss of protein through nonsense-mediated RNA decay [chen-2023-ephb4-rasa1-summary]. The disease mechanism appears to involve haploinsufficiency, with a "second hit" model proposed for lesion development. According to this model, somatic mutation of the inherited wild-type RASA1 allele in endothelial cells during development creates RASA1-null cells that drive lesion formation [chen-2023-ephb4-rasa1-summary]. This model has been supported by identification of biallelic RASA1 inactivation in lesional tissue.

Beyond CM-AVM, RASA1 mutations have been associated with vein of Galen arteriovenous malformation (VGAM), lymphatic-related hydrops fetalis, central conducting lymphatic anomaly, and lymphedema [chen-2023-ephb4-rasa1-summary]. RASA1 and EPHB4 are required for the development of all three types of vascular valves—lymphatic vessel valves, lymphovenous valves, and venous valves—and maintenance of lymphatic vessel valves in adults depends upon continued RASA1 catalytic activity.

The mechanism by which RASA1 deficiency causes vascular malformations has been partially elucidated. Dysregulated Ras-MAPK activation in RASA1-deficient endothelial cells impairs secretion of collagen IV, a critical extracellular matrix component. Excessive MAPK signaling leads to increased collagen proline and lysine hydroxylation, which impairs proper collagen folding and cellular export [chen-2023-ephb4-rasa1-summary]. Retention of misfolded collagen in the endoplasmic reticulum triggers the unfolded protein response and subsequent endothelial cell apoptosis. This mechanistic understanding has identified potential therapeutic targets, including MAPK pathway inhibitors, collagen modification inhibitors, and ER chaperone agonists.

Open Questions

Despite extensive research on RASA1 spanning more than three decades since its discovery, several important questions remain unresolved:

1. Context-dependent signaling outcomes: EphB4-RASA1 signaling inhibits the Ras-MAPK pathway in endothelial cells but activates this pathway in other cell types such as hepatic stellate cells [chen-2023-ephb4-rasa1-summary]. The molecular basis for these opposite outcomes in different cellular contexts remains unclear.

2. C2 domain catalytic contribution: While recent work has demonstrated that the C2 domain directly augments GAP catalytic activity through interaction with Ras, the precise structural mechanism and the physiological importance of this enhancement require further investigation.

3. Tissue-specific phenotypes: Some families with RASA1 mutations present with lymphatic-only phenotypes despite the two-hit model predicting vascular involvement [chen-2023-ephb4-rasa1-summary]. The basis for this phenotypic variability is not understood.

4. Therapeutic window for established lesions: It remains unclear whether vascular malformations that have already formed maintain dysregulated Ras-MAPK signaling, which would be necessary for pathway-targeted therapies to be effective [chen-2023-ephb4-rasa1-summary].

5. Functional specificity among RasGAPs: Ten RasGAPs exist in mammals, yet RASA1 deficiency produces specific phenotypes despite the presence of other family members. Understanding how specificity is achieved, and whether compensation occurs, remains an open area of investigation.

6. Integration of catalytic and scaffolding functions: RASA1 serves both as an enzyme and as a multidomain scaffold for signaling complexes. How these two functions are coordinated, and whether they can be separated therapeutically, warrants further study.

References

1. [trahey-1987-gap-discovery-abstract] Trahey M, McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science. 1987 Oct 23;238(4826):542-5. PMID: 2821624. DOI: 10.1126/science.2821624

2. [scheffzek-1996-gap334-structure-summary] Scheffzek K, Lautwein A, Kabsch W, Ahmadian MR, Wittinghofer A. Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras. Nature. 1996 Dec 12;384(6609):591-6. PMID: 8955277. DOI: 10.1038/384591a0

3. [scheffzek-1997-ras-rasgap-complex-summary] Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997 Jul 18;277(5324):333-8. PMID: 9219684. DOI: 10.1126/science.277.5324.333. PDB: 1WQ1

4. [henkemeyer-1995-rasgap-knockout-abstract] Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, Shih TS, Jacks T, Pawson T. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 1995 Oct 26;377(6551):695-701. PMID: 7477259. DOI: 10.1038/377695a0

5. [grewal-2005-annexin-a6-abstract] Grewal T, Evans R, Rentero C, Tebar F, Cubells L, de Diego I, Kirchhoff MF, Hughes WE, Heeren J, Rye KA, Rinninger F, Daly RJ, Pol A, Enrich C. Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. Oncogene. 2005 Sep 1;24(38):5809-20. PMID: 15940262. DOI: 10.1038/sj.onc.1208743

6. [pamonsinlapatham-2009-rasgap-multiinteracting-summary] Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, Allain B, Toccafondi M, Garbay C, Raynaud F. p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie. 2009 Mar;91(3):320-8. PMID: 19022332. DOI: 10.1016/j.biochi.2008.10.010

7. [scheffzek-2019-rasgap-review-summary] Scheffzek K, Shivalingaiah G. Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions. Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a031500. PMID: 29610147. PMCID: PMC6396337. DOI: 10.1101/cshperspect.a031500

8. [stiegler-2022-sh2-tandem-summary] Stiegler AL, Vish KJ, Boggon TJ. Tandem engagement of phosphotyrosines by the dual SH2 domains of p120RasGAP. Structure. 2022 Dec 1;30(12):1603-1614.e5. PMID: 36323259. PMCID: PMC9722645. DOI: 10.1016/j.str.2022.10.009. PDB: 8DGQ

9. [chen-2023-ephb4-rasa1-summary] Chen D, Van der Ent MA, Lartey NL, King PD. EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans. Pharmaceuticals (Basel). 2023 Jan 23;16(2):165. PMID: 37259315. PMCID: PMC9959185. DOI: 10.3390/ph16020165

10. [wen-1998-rasgap-cleavage-abstract] Wen LP, Madani K, Martin GA, Rosen GD. Proteolytic cleavage of ras GTPase-activating protein during apoptosis. Cell Death Differ. 1998 Sep;5(9):729-34. PMID: 10200531. DOI: 10.1038/sj.cdd.4400409

11. [yang-2001-caspase-rasgap-summary] Yang JY, Widmann C. Antiapoptotic Signaling Generated by Caspase-Induced Cleavage of RasGAP. Mol Cell Biol. 2001 Aug;21(16):5346-58. PMID: 11463818. PMCID: PMC87258. DOI: 10.1128/MCB.21.16.5346-5358.2001

Citations

1. chen-2023-ephb4-rasa1-summary.md
2. grewal-2005-annexin-a6-abstract.md
3. henkemeyer-1995-rasgap-knockout-abstract.md
4. pamonsinlapatham-2009-rasgap-multiinteracting-summary.md
5. scheffzek-1996-gap334-structure-summary.md
6. scheffzek-1997-ras-rasgap-complex-summary.md
7. scheffzek-2019-rasgap-review-summary.md
8. stiegler-2022-sh2-tandem-summary.md
9. trahey-1987-gap-discovery-abstract.md
10. wen-1998-rasgap-cleavage-abstract.md
11. yang-2001-caspase-rasgap-summary.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and identity verification
- We verified the target: human RASA1 (UniProt P20936), also known as p120RasGAP, matches the provided description. Literature consistently describes a multi‑domain protein with N‑terminal SH2–SH3–SH2 modules, central PH and C2 domains, and a C‑terminal catalytic RasGAP domain, aligning with UniProt domains and the user’s brief (e.g., Stewart & Clark 2020, Journal of Cell Science; URL: https://doi.org/10.1242/jcs.238865, Feb 2020) (stewart2020pumpingthebrakes pages 2-3, stewart2020pumpingthebrakes pages 3-4). The organismal context is Homo sapiens throughout.

Key concepts and definitions (current understanding)
- Primary biochemical function: RASA1 is a Ras GTPase‑activating protein that accelerates GTP hydrolysis on Ras, thereby turning off Ras signaling and constraining downstream RAF–MEK–ERK and PI3K–AKT pathways (reviewed in Oncology Reports 2020; URL: https://doi.org/10.3892/or.2020.7807, Oct 2020) (zhang2020roleofrasa1 pages 1-2, zhang2020roleofrasa1 pages 8-9). The GAP catalytic activity resides in the C‑terminal RasGAP domain, while SH2/SH3/PH/C2 modules mediate recruitment and regulation (Journal of Cell Science 2020; URL: https://doi.org/10.1242/jcs.238865, Feb 2020) (stewart2020pumpingthebrakes pages 2-3, stewart2020pumpingthebrakes pages 3-4).
- Domain architecture: Tandem SH2–SH3–SH2, PH, C2, and RasGAP domains (Structure 2022; URL: https://doi.org/10.1016/j.str.2022.10.009, Dec 2022) (stiegler2022tandemengagementof pages 15-16). SH2 domains bind phosphotyrosines in partner proteins; the SH3 domain is atypical and can bind non‑PxxP targets; PH and C2 mediate lipid/membrane interactions; the GAP domain engages Ras to stimulate hydrolysis (stewart2020pumpingthebrakes pages 2-3, stiegler2022tandemengagementof pages 15-16).
- Cellular localization and membrane recruitment: RASA1 is cytosolic but is recruited to membranes through (i) SH2 recognition of phosphotyrosyl motifs in activated receptors/adaptors and (ii) lipid binding via PH/C2, often Ca2+‑sensitive; such modular domains are a common strategy for GAPs to reach membrane‑anchored GTPases (Bioscience Reports 2024; URL: https://doi.org/10.1042/bsr20231420, May 2024; Journal of Cell Science 2020) (odonoghue2024rolesofg pages 7-7, stewart2020pumpingthebrakes pages 3-4).

Recent mechanistic and structural advances (with emphasis on 2022–2024)
- Tandem SH2 engagement and partner specificity: Biophysical/structural work shows p120RasGAP’s dual SH2 domains engage doubly phosphorylated motifs on different partners (EphB4, p190RhoGAP/ARHGAP35, Dok1) with distinct modes and affinities; SH2 binding organizes spatial recruitment without altering intrinsic RasGAP catalytic activity (JBC 2023; URL: https://doi.org/10.1016/j.jbc.2023.105098, Sep 2023; Structure 2022) (vish2023diversep120rasgapinteractions pages 1-2, stiegler2022tandemengagementof pages 15-16).
- Ras–Rho crosstalk via SH3: A co‑crystal structure established that RASA1’s atypical SH3 domain directly binds the DLC1 RhoGAP domain at a site overlapping the RhoA interface, inhibiting DLC1’s RhoGAP activity and providing a molecular mechanism for Ras–Rho pathway crosstalk (Nature Communications 2022; URL: https://doi.org/10.1038/s41467-022-32541-4, Aug 2022) (chau2022sh3domainregulation pages 6-7, chau2022sh3domainregulation pages 1-2).
- Post‑translational control of Ras–GAP interactions: Ubiquitination of Ras at K128 (observed for NRAS/KRAS) increases binding interfaces for GAPs (NF1 and RASA1), enhancing GAP‑mediated hydrolysis. Growth factor stimulation transiently increases K128 ubiquitination, restricting wild‑type Ras activation; reduced K128 ubiquitination activates Ras signaling and promotes tumorigenesis in models (EMBO Journal 2024; URL: https://doi.org/10.1038/s44318-024-00146-w, Jun 2024) (romano2025arteriovenouscerebralhighflow pages 6-7).

Pathways, partners, and precise roles in signaling
- Pathways: RASA1 is a principal negative regulator of Ras→RAF–MEK–ERK, and influences PI3K–AKT outputs; in endothelium, RASA1 deficiency leads to ERK hyperactivation and vascular malformation phenotypes (review and models: Journal of Cell Science 2020; 2022 thesis; URLs: https://doi.org/10.1242/jcs.238865; https://doi.org/10.11575/prism/40578) (stewart2020pumpingthebrakes pages 2-3, gosal2025theintersectionof pages 28-31, greyssonwong2022developmentofrasa1 pages 26-31).
- Key binding partners: EphB4 (receptor tyrosine kinase), p190RhoGAP (ARHGAP35), Dok1 — all recruit p120RasGAP via phosphotyrosines; DLC1 is bound by the SH3 domain leading to inhibition of DLC1’s RhoGAP activity; these interactions coordinate Ras and Rho signaling at membranes (JBC 2023; Nat Commun 2022) (vish2023diversep120rasgapinteractions pages 1-2, chau2022sh3domainregulation pages 6-7).
- Endothelial/vascular functions: Endothelial RASA1 activity is necessary for normal embryonic vascular development. Loss increases ERK signaling in AVM lesions; preclinical work supports MEK/ERK pathway dependence (2022 thesis; URL: https://doi.org/10.11575/prism/40578) (gosal2025theintersectionof pages 28-31, greyssonwong2022developmentofrasa1 pages 26-31).

Genetics, clinical spectrum, and statistics (RASA1-related vascular anomalies)
- Syndrome and spectrum: Heterozygous germline loss‑of‑function RASA1 variants cause capillary malformation–arteriovenous malformation (CM‑AVM) syndrome with variable expressivity, including multifocal cutaneous capillary malformations, fast‑flow AVMs/AVFs (intracranial, intraspinal, extremities), and occasionally vein of Galen aneurysmal malformation (VGAM). Intrafamilial variability is common (Genes 2023; URL: https://doi.org/10.3390/genes14030549, Feb 2023) (coccia2023prenatalclinicalfindings pages 12-13, coccia2023prenatalclinicalfindings pages 8-9).
- Two‑hit/second‑hit mechanism and mosaicism: Multiple lines of evidence support a germline‑plus‑somatic “second‑hit” model for RASA1, with somatic inactivating events in lesions contributing to focal malformations and incomplete penetrance. Recent clinical genetics work in pediatric high‑flow cerebrovascular malformations emphasizes this model and reports both inherited and de novo RASA1 variants (Frontiers in Genetics 2025; URL: https://doi.org/10.3389/fgene.2025.1430657, Mar 2025) (romano2025arteriovenouscerebralhighflow pages 6-7). Experimental models (zebrafish rasa1 mutants) further support ERK‑driven pathology and informed early MEK inhibition strategies (gosal2025theintersectionof pages 28-31).
- Prenatal presentations and quantitative data: In a 2023 summary of 21 prenatal‑onset cases of RASA1‑related CM‑AVM, reported prenatal findings included polyhydramnios ≈38%, non‑immune hydrops ≈24%, and chylothorax ≈15%; mortality in prenatal‑onset cases was ≈30%. Postnatal features included cutaneous capillary malformations ≈73% and vascular malformations/AVMs ≈65% (Genes 2023; URL: https://doi.org/10.3390/genes14030549, Feb 2023) (coccia2023prenatalclinicalfindings pages 8-9). Clinical heterogeneity was highlighted by mildly affected carriers in the same families (coccia2023prenatalclinicalfindings pages 11-12).
- Clinical spectrum detail: Reviews of vascular anomalies (Hematology 2024) note RASA1 CM‑AVM and a related EPHB4 CM‑AVM2 with shared deregulation of Ras–MAPK signaling, and discuss expanding presentations including lymphatic involvement (URL: https://doi.org/10.1182/hematology.2024000598, Dec 2024) (seront2024molecularlandscapeand pages 8-9). A 2024 review oriented to interventional radiologists emphasizes genetics‑informed diagnosis and the importance of biopsy/somatic testing in management planning (Seminars in Interventional Radiology 2024; URL: https://doi.org/10.1055/s-0044-1791204, Aug 2024) (seront2024molecularlandscapeand pages 8-9).

Testing recommendations and expert guidance (2023–2024)
- Genetic testing: The 2024 VASCERN‑VASCA consensus assesses gene–disease associations and provides recommendations for testing somatic variants in vascular anomalies. It supports inclusion of Ras/MAPK pathway genes (including RASA1 and EPHB4) on targeted gene panels, emphasizes sensitivity for low‑level mosaicism in lesional tissue, and encourages standardized variant interpretation (Orphanet Journal of Rare Diseases 2024; URL: https://doi.org/10.1186/s13023-024-03196-9, May 2024) (seront2024molecularlandscapeand pages 8-9). Case‑based recommendations advocate germline RASA1 testing with consideration of somatic/lesional testing where feasible, due to frequent second‑hit mechanisms and variable penetrance (Frontiers in Genetics 2025; URL: https://doi.org/10.3389/fgene.2025.1430657, Mar 2025) (romano2025arteriovenouscerebralhighflow pages 6-7).
- Clinical surveillance: For carriers/newborns with even subtle cutaneous CMs, second‑level imaging to exclude occult high‑flow lesions is recommended based on prenatal/postnatal cohorts (Genes 2023) (coccia2023prenatalclinicalfindings pages 11-12).

Therapeutic implications and real‑world implementations
- Targeted therapies in models and translational practice: Preclinical RASA1‑deficiency models (mouse/zebrafish) show that MEK/ERK pathway inhibitors can mitigate hemorrhage/edema or improve survival, consistent with ERK hyperactivation in AVMs (2022 thesis; URL: https://doi.org/10.11575/prism/40578) (greyssonwong2022developmentofrasa1 pages 26-31, gosal2025theintersectionof pages 28-31). Contemporary clinical reviews of vascular anomalies advocate molecular classification and selective repurposing of pathway inhibitors (e.g., MEK inhibitors) for fast‑flow malformations driven by Ras/MAPK activation (Hematology 2024; URL: https://doi.org/10.1182/hematology.2024000598, Dec 2024) (seront2024molecularlandscapeand pages 8-9).
- Mechanistic avenues for modulation: The 2024 EMBO Journal study showing Ras K128 ubiquitination enhances NF1/RASA1 engagement suggests a post‑translational axis that could be leveraged to restore RasGAP restraint in disease contexts (URL: https://doi.org/10.1038/s44318-024-00146-w, Jun 2024) (romano2025arteriovenouscerebralhighflow pages 6-7).

Cancer relevance
- RASA1 as a tumor suppressor: Reduced RASA1 function contributes to Ras pathway activation in cancers; reviews summarize downregulation/mutation across tumor types and oncogenic impacts of miRNA‑mediated repression (Journal of Cell Science 2020; Oncology Reports 2020; URLs above) (stewart2020pumpingthebrakes pages 2-3, zhang2020roleofrasa1 pages 8-9, zhang2020roleofrasa1 pages 1-2, bellazzo2020cuttingthebrakes pages 15-17). The K128‑Ub study connects increased GAP engagement to constrained Ras outputs, underscoring how loss of such regulation can foster tumorigenesis (EMBO Journal 2024; URL above) (romano2025arteriovenouscerebralhighflow pages 6-7).

Subcellular site of action and substrate specificity
- Site and substrate: RASA1 acts at cytoplasmic leaflets of membranes where Ras is anchored, recruited by phosphotyrosine‑dependent interactions and lipid‑binding modules. It catalyzes GTP hydrolysis on Ras (H‑, K‑, N‑Ras) and has reported activity toward RRas/Rap in vitro; endothelial studies implicate effects on integrins and basement membrane dynamics (Journal of Cell Science 2020; Oncology Reports 2020; thesis 2022; URLs above) (stewart2020pumpingthebrakes pages 2-3, zhang2020roleofrasa1 pages 1-2, greyssonwong2022developmentofrasa1 pages 26-31).

Open questions and limitations
- Precise penetrance of specific end‑organ lesions (e.g., true population‑level VGAM rates in RASA1 carriers) and quantitative second‑hit frequencies require further large‑scale datasets; current evidence supports incomplete penetrance and frequent two‑hit mechanisms but comprehensive population statistics were not available in the sources reviewed here (romano2025arteriovenouscerebralhighflow pages 6-7, coccia2023prenatalclinicalfindings pages 8-9, seront2024molecularlandscapeand pages 8-9).

Embedded summary table
| Feature | Summary | Representative recent sources (URL; year) (context IDs) |
|---|---|---|
| Identity verification | UniProt P20936; gene RASA1 (aka p120RasGAP, GAP); human (Homo sapiens). | https://doi.org/10.1242/jcs.238865 (2020); https://doi.org/10.3892/or.2020.7807 (2020) (stewart2020pumpingthebrakes pages 2-3, zhang2020roleofrasa1 pages 1-2) |
| Domain architecture & roles | Tandem N-terminal SH2–SH3–SH2, central PH and C2-like modules, C-terminal RasGAP catalytic domain — regulatory domains mediate phosphotyrosine and membrane/lipid interactions, GAP domain stimulates Ras GTP hydrolysis. | https://doi.org/10.1016/j.str.2022.10.009 (2022); https://doi.org/10.1242/jcs.238865 (2020) (stiegler2022tandemengagementof pages 15-16, stewart2020pumpingthebrakes pages 2-3) |
| Core functions | Stimulates GTP hydrolysis of RAS (and activity toward RRas/Rap reported); negative regulator of RAS→RAF–MEK–ERK and modulates PI3K–AKT signaling and endothelial behaviors. | https://doi.org/10.3892/or.2020.7807 (2020); https://doi.org/10.11575/prism/40578 (2022) (zhang2020roleofrasa1 pages 8-9, greyssonwong2022developmentofrasa1 pages 26-31) |
| Membrane recruitment / localization | Recruited to membranes via Ca2+-sensitive PH/C2 lipid interactions and SH2 binding to phosphorylated receptors/partners; SH2/SH3 modules can also modulate membrane association via partner docking. | https://doi.org/10.1242/jcs.238865 (2020); https://doi.org/10.1042/bsr20231420 (2024) (stewart2020pumpingthebrakes pages 3-4, odonoghue2024rolesofg pages 7-7) |
| Key binding partners | EphB4, Dok1, p190RhoGAP (ARHGAP35), DLC1 (inhibited via p120RasGAP SH3), filamin A; links to endothelial collagen IV export/valve development. | https://doi.org/10.1016/j.jbc.2023.105098 (2023); https://doi.org/10.1038/s41467-022-32541-4 (2022); https://doi.org/10.11575/prism/40578 (2022) (vish2023diversep120rasgapinteractions pages 1-2, chau2022sh3domainregulation pages 6-7, greyssonwong2022developmentofrasa1 pages 26-31) |
| 2022–2024 mechanistic advances | (1) Structural/biophysical evidence that tandem SH2s engage doubly phosphorylated motifs with partner-specific modes; (2) Co-crystal and biochemical demonstration that the atypical p120RasGAP SH3 binds/inhibits DLC1 RhoGAP (Ras–Rho crosstalk); (3) Recent reports show post-translational modifications of RAS (e.g., K128 ubiquitination) can enhance GAP (NF1/RASA1) binding — modulating GAP efficacy. | https://doi.org/10.1016/j.str.2022.10.009 (2022); https://doi.org/10.1038/s41467-022-32541-4 (2022); https://doi.org/10.1016/j.jbc.2023.105098 (2023) (stiegler2022tandemengagementof pages 15-16, chau2022sh3domainregulation pages 6-7, vish2023diversep120rasgapinteractions pages 1-2) |
| Pathways regulated & crosstalk | Directly constrains RAS→RAF–MEK–ERK and influences PI3K–AKT signaling; intersects with Notch/BMP mechano-signaling in endothelium and modulates Rho signaling via DLC1 interaction. | (model & review evidence) https://doi.org/10.11575/prism/40578 (2022); https://doi.org/10.3892/or.2020.7807 (2020) (gosal2025theintersectionof pages 28-31, zhang2020roleofrasa1 pages 8-9) |
| Genetic / clinical associations | Germline loss‑of‑function RASA1 variants cause capillary malformation–arteriovenous malformation (CM‑AVM) spectrum (including VGAM/VOGM reports); phenotype shows incomplete penetrance, marked variable expressivity and evidence for a germline + somatic "second‑hit" model. Prenatal series: polyhydramnios ~38%, nonimmune hydrops ~24%, prenatal-onset death ≈30% (cohorts summarized). | https://doi.org/10.3390/genes14030549 (2023); https://doi.org/10.1182/hematology.2024000598 (2024) (coccia2023prenatalclinicalfindings pages 8-9, seront2024molecularlandscapeand pages 8-9) |
| Testing guidance | Recent consensus reviews recommend inclusion of RASA1 on vascular‑anomaly gene panels, consideration of lesional (somatic/mosaic) testing for second‑hit detection, and multidisciplinary genetic counseling (VASCERN‑VASCA recommendations). | https://doi.org/10.1186/s13023-024-03196-9 (2024); https://doi.org/10.3389/fgene.2025.1430657 (2025) (seront2024molecularlandscapeand pages 8-9, romano2025arteriovenouscerebralhighflow pages 6-7) |
| Therapeutic implications / applications | Preclinical rescue of RASA1-deficient vascular phenotypes with MEK/ERK pathway inhibitors (mouse/zebrafish models) supports MAPK-targeted strategies; translational approaches include repurposing MAPK/MEK inhibitors for selected high‑flow lesions and investigating multi‑pathway interventions. | https://doi.org/10.11575/prism/40578 (2022); (model work) (greyssonwong2022developmentofrasa1 pages 26-31, gosal2025theintersectionof pages 28-31) |

Table: Compact, evidence‑linked summary of human RASA1 identity, domains, functions, membrane recruitment, partners, 2022–2024 mechanistic advances, pathways, clinical genetics, testing guidance, and therapeutic implications with representative recent sources.

Conclusions
Human RASA1 (p120RasGAP) is a modular RasGAP that integrates phosphotyrosine‑ and lipid‑dependent recruitment to inactivate Ras at membranes, constraining RAF–MEK–ERK and PI3K–AKT signaling. Recent advances clarify tandem SH2 engagement with doubly phosphorylated partners (EphB4, p190RhoGAP, Dok1), Ras–Rho crosstalk via SH3‑mediated inhibition of DLC1, and a ubiquitination‑dependent mechanism (Ras K128‑Ub) that enhances GAP binding. Clinically, heterozygous RASA1 variants cause the CM‑AVM spectrum, with incomplete penetrance, prenatal manifestations, and support for germline‑plus‑somatic second hits; contemporary guidance recommends including RASA1 in gene panels and pursuing lesional testing where possible. Preclinical evidence supports MAPK‑targeted strategies (e.g., MEK inhibition) for RASA1‑driven AVMs, aligning with precision‑medicine approaches to vascular anomalies (stiegler2022tandemengagementof pages 15-16, vish2023diversep120rasgapinteractions pages 1-2, chau2022sh3domainregulation pages 6-7, romano2025arteriovenouscerebralhighflow pages 6-7, coccia2023prenatalclinicalfindings pages 8-9, seront2024molecularlandscapeand pages 8-9, greyssonwong2022developmentofrasa1 pages 26-31, gosal2025theintersectionof pages 28-31, stewart2020pumpingthebrakes pages 2-3, zhang2020roleofrasa1 pages 1-2).

References (URLs and dates indicated above; formal support via context IDs): (stewart2020pumpingthebrakes pages 2-3, stewart2020pumpingthebrakes pages 3-4, zhang2020roleofrasa1 pages 1-2, zhang2020roleofrasa1 pages 8-9, stiegler2022tandemengagementof pages 15-16, odonoghue2024rolesofg pages 7-7, vish2023diversep120rasgapinteractions pages 1-2, chau2022sh3domainregulation pages 6-7, chau2022sh3domainregulation pages 1-2, romano2025arteriovenouscerebralhighflow pages 6-7, gosal2025theintersectionof pages 28-31, greyssonwong2022developmentofrasa1 pages 26-31, coccia2023prenatalclinicalfindings pages 12-13, coccia2023prenatalclinicalfindings pages 8-9, coccia2023prenatalclinicalfindings pages 11-12, seront2024molecularlandscapeand pages 8-9, bellazzo2020cuttingthebrakes pages 15-17)

References

1. (stewart2020pumpingthebrakes pages 2-3): Desmond R. Harrell Stewart and Geoffrey J. Clark. Pumping the brakes on ras – negative regulators and death effectors of ras. Journal of Cell Science, Feb 2020. URL: https://doi.org/10.1242/jcs.238865, doi:10.1242/jcs.238865. This article has 32 citations and is from a domain leading peer-reviewed journal.

2. (stewart2020pumpingthebrakes pages 3-4): Desmond R. Harrell Stewart and Geoffrey J. Clark. Pumping the brakes on ras – negative regulators and death effectors of ras. Journal of Cell Science, Feb 2020. URL: https://doi.org/10.1242/jcs.238865, doi:10.1242/jcs.238865. This article has 32 citations and is from a domain leading peer-reviewed journal.

3. (zhang2020roleofrasa1 pages 1-2): Yanhua Zhang, Yue Li, Quanyue Wang, Bo Su, Hui Xu, Yang Sun, Pei Sun, Rumeng Li, Xiaochun Peng, and Jun Cai. Role of rasa1 in cancer: a review and update. Oncology Reports, 44:2386-2396, Oct 2020. URL: https://doi.org/10.3892/or.2020.7807, doi:10.3892/or.2020.7807. This article has 64 citations and is from a peer-reviewed journal.

4. (zhang2020roleofrasa1 pages 8-9): Yanhua Zhang, Yue Li, Quanyue Wang, Bo Su, Hui Xu, Yang Sun, Pei Sun, Rumeng Li, Xiaochun Peng, and Jun Cai. Role of rasa1 in cancer: a review and update. Oncology Reports, 44:2386-2396, Oct 2020. URL: https://doi.org/10.3892/or.2020.7807, doi:10.3892/or.2020.7807. This article has 64 citations and is from a peer-reviewed journal.

5. (stiegler2022tandemengagementof pages 15-16): Amy L. Stiegler, Kimberly J. Vish, and Titus J. Boggon. Tandem engagement of phosphotyrosines by the dual sh2 domains of p120rasgap. Structure, 30:1603-1614.e5, Dec 2022. URL: https://doi.org/10.1016/j.str.2022.10.009, doi:10.1016/j.str.2022.10.009. This article has 7 citations and is from a domain leading peer-reviewed journal.

6. (odonoghue2024rolesofg pages 7-7): Lorna O'Donoghue and Albert Smolenski. Roles of g proteins and their gtpase-activating proteins in platelets. Bioscience Reports, May 2024. URL: https://doi.org/10.1042/bsr20231420, doi:10.1042/bsr20231420. This article has 6 citations and is from a peer-reviewed journal.

7. (vish2023diversep120rasgapinteractions pages 1-2): Kimberly J. Vish, Amy L. Stiegler, and Titus J. Boggon. Diverse p120rasgap interactions with doubly phosphorylated partners ephb4, p190rhogap, and dok1. Journal of Biological Chemistry, 299:105098, Sep 2023. URL: https://doi.org/10.1016/j.jbc.2023.105098, doi:10.1016/j.jbc.2023.105098. This article has 10 citations and is from a domain leading peer-reviewed journal.

8. (chau2022sh3domainregulation pages 6-7): Jocelyn E. Chau, Kimberly J. Vish, Titus J. Boggon, and Amy L. Stiegler. Sh3 domain regulation of rhogap activity: crosstalk between p120rasgap and dlc1 rhogap. Nature Communications, Aug 2022. URL: https://doi.org/10.1038/s41467-022-32541-4, doi:10.1038/s41467-022-32541-4. This article has 18 citations and is from a highest quality peer-reviewed journal.

9. (chau2022sh3domainregulation pages 1-2): Jocelyn E. Chau, Kimberly J. Vish, Titus J. Boggon, and Amy L. Stiegler. Sh3 domain regulation of rhogap activity: crosstalk between p120rasgap and dlc1 rhogap. Nature Communications, Aug 2022. URL: https://doi.org/10.1038/s41467-022-32541-4, doi:10.1038/s41467-022-32541-4. This article has 18 citations and is from a highest quality peer-reviewed journal.

10. (romano2025arteriovenouscerebralhighflow pages 6-7): Ferruccio Romano, Patrizia De Marco, Giulia Amico, Marisa Mallamaci, Marco Pavanello, Gianluca Piatelli, Marcello Scala, Federico Zara, Francesca Faravelli, Mariasavina Severino, Domenico Tortora, Francesco Pasetti, Lucio Castellan, Silvia Buratti, and Valeria Capra. Arteriovenous cerebral high-flow shunts: genetic analysis of patients from a pediatric tertiary care center. Frontiers in Genetics, Mar 2025. URL: https://doi.org/10.3389/fgene.2025.1430657, doi:10.3389/fgene.2025.1430657. This article has 0 citations and is from a peer-reviewed journal.

11. (gosal2025theintersectionof pages 28-31): JK Gosal. The intersection of signaling and arteriovenous malformation progression in a rasa1 mutant model. Unknown journal, 2025.

12. (greyssonwong2022developmentofrasa1 pages 26-31): Jasper Greysson-Wong. Development of rasa1 arteriovenous malformations. Other, Dec 2022. URL: https://doi.org/10.11575/prism/40578, doi:10.11575/prism/40578. This article has 0 citations.

13. (coccia2023prenatalclinicalfindings pages 12-13): Emanuele Coccia, Lara Valeri, Roberta Zuntini, Stefano Giuseppe Caraffi, Francesca Peluso, Luca Pagliai, Antonietta Vezzani, Zaira Pietrangiolillo, Francesco Leo, Nives Melli, Valentina Fiorini, Andrea Greco, Francesca Romana Lepri, Elisa Pisaneschi, Annabella Marozza, Diana Carli, Alessandro Mussa, Francesca Clementina Radio, Beatrice Conti, Maria Iascone, Giancarlo Gargano, Antonio Novelli, Marco Tartaglia, Orsetta Zuffardi, Maria Francesca Bedeschi, and Livia Garavelli. Prenatal clinical findings in rasa1-related capillary malformation-arteriovenous malformation syndrome. Genes, 14:549, Feb 2023. URL: https://doi.org/10.3390/genes14030549, doi:10.3390/genes14030549. This article has 11 citations and is from a poor quality or predatory journal.

14. (coccia2023prenatalclinicalfindings pages 8-9): Emanuele Coccia, Lara Valeri, Roberta Zuntini, Stefano Giuseppe Caraffi, Francesca Peluso, Luca Pagliai, Antonietta Vezzani, Zaira Pietrangiolillo, Francesco Leo, Nives Melli, Valentina Fiorini, Andrea Greco, Francesca Romana Lepri, Elisa Pisaneschi, Annabella Marozza, Diana Carli, Alessandro Mussa, Francesca Clementina Radio, Beatrice Conti, Maria Iascone, Giancarlo Gargano, Antonio Novelli, Marco Tartaglia, Orsetta Zuffardi, Maria Francesca Bedeschi, and Livia Garavelli. Prenatal clinical findings in rasa1-related capillary malformation-arteriovenous malformation syndrome. Genes, 14:549, Feb 2023. URL: https://doi.org/10.3390/genes14030549, doi:10.3390/genes14030549. This article has 11 citations and is from a poor quality or predatory journal.

15. (coccia2023prenatalclinicalfindings pages 11-12): Emanuele Coccia, Lara Valeri, Roberta Zuntini, Stefano Giuseppe Caraffi, Francesca Peluso, Luca Pagliai, Antonietta Vezzani, Zaira Pietrangiolillo, Francesco Leo, Nives Melli, Valentina Fiorini, Andrea Greco, Francesca Romana Lepri, Elisa Pisaneschi, Annabella Marozza, Diana Carli, Alessandro Mussa, Francesca Clementina Radio, Beatrice Conti, Maria Iascone, Giancarlo Gargano, Antonio Novelli, Marco Tartaglia, Orsetta Zuffardi, Maria Francesca Bedeschi, and Livia Garavelli. Prenatal clinical findings in rasa1-related capillary malformation-arteriovenous malformation syndrome. Genes, 14:549, Feb 2023. URL: https://doi.org/10.3390/genes14030549, doi:10.3390/genes14030549. This article has 11 citations and is from a poor quality or predatory journal.

16. (seront2024molecularlandscapeand pages 8-9): Emmanuel Seront, Angela Queisser, Laurence M. Boon, and Miikka Vikkula. Molecular landscape and classification of vascular anomalies. Hematology, 2024:700-708, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000598, doi:10.1182/hematology.2024000598. This article has 5 citations and is from a peer-reviewed journal.

17. (bellazzo2020cuttingthebrakes pages 15-17): Arianna Bellazzo and Licio Collavin. Cutting the brakes on ras—cytoplasmic gaps as targets of inactivation in cancer. Cancers, 12:3066, Oct 2020. URL: https://doi.org/10.3390/cancers12103066, doi:10.3390/cancers12103066. This article has 19 citations and is from a poor quality or predatory journal.

Citations

1. stiegler2022tandemengagementof pages 15-16
2. romano2025arteriovenouscerebralhighflow pages 6-7
3. gosal2025theintersectionof pages 28-31
4. coccia2023prenatalclinicalfindings pages 8-9
5. coccia2023prenatalclinicalfindings pages 11-12
6. seront2024molecularlandscapeand pages 8-9
7. stewart2020pumpingthebrakes pages 2-3
8. stewart2020pumpingthebrakes pages 3-4
9. odonoghue2024rolesofg pages 7-7
10. coccia2023prenatalclinicalfindings pages 12-13
11. bellazzo2020cuttingthebrakes pages 15-17
12. https://doi.org/10.1242/jcs.238865,
13. https://doi.org/10.3892/or.2020.7807,
14. https://doi.org/10.1016/j.str.2022.10.009,
15. https://doi.org/10.1042/bsr20231420,
16. https://doi.org/10.1016/j.jbc.2023.105098,
17. https://doi.org/10.1038/s41467-022-32541-4,
18. https://doi.org/10.1038/s44318-024-00146-w,
19. https://doi.org/10.1242/jcs.238865;
20. https://doi.org/10.11575/prism/40578
21. https://doi.org/10.3390/genes14030549,
22. https://doi.org/10.3389/fgene.2025.1430657,
23. https://doi.org/10.1182/hematology.2024000598,
24. https://doi.org/10.1055/s-0044-1791204,
25. https://doi.org/10.1186/s13023-024-03196-9,
26. https://doi.org/10.1242/jcs.238865
27. https://doi.org/10.3892/or.2020.7807
28. https://doi.org/10.1016/j.str.2022.10.009
29. https://doi.org/10.1042/bsr20231420
30. https://doi.org/10.1016/j.jbc.2023.105098
31. https://doi.org/10.1038/s41467-022-32541-4
32. https://doi.org/10.3390/genes14030549
33. https://doi.org/10.1182/hematology.2024000598
34. https://doi.org/10.1186/s13023-024-03196-9
35. https://doi.org/10.3389/fgene.2025.1430657
36. https://doi.org/10.11575/prism/40578,
37. https://doi.org/10.3390/cancers12103066,

Introduction

Ras p21 protein activator 1 (RASA1) is a human gene encoding a 120 kDa protein known as p120 RasGAP – the first identified GTPase-activating protein (GAP) for Ras (pmc.ncbi.nlm.nih.gov). As a Ras-specific GAP, RASA1 negatively regulates Ras signaling by accelerating the hydrolysis of Ras-bound GTP, thereby switching Ras from its active (GTP-bound) state to an inactive (GDP-bound) state (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This “off switch” function is critical for controlling Ras-mediated pathways that drive cell proliferation, differentiation, and survival. RASA1 is ubiquitously expressed and is essential for development – mice lacking RASA1 die by mid-gestation with severe vascular defects (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Germline loss-of-function mutations in RASA1 cause capillary malformation-arteriovenous malformation (CM-AVM) syndrome in humans, underlining the gene’s crucial role in blood vessel formation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In brief, RASA1 acts as a key “brake” on Ras signaling, ensuring that Ras activation is properly terminated in space and time. Below, we elaborate on RASA1’s structure, molecular function, cellular localization, and involvement in major signaling pathways, drawing on current research and expert analyses.

Protein Structure and Localization

The RASA1 protein is a multidomain signaling molecule that integrates several modules for targeting and regulation. Its C-terminal portion comprises the catalytic RasGAP domain (also called the GAP-related domain, GRD, amino acids ~718–1047) (pmc.ncbi.nlm.nih.gov), which is responsible for stimulating Ras GTP hydrolysis. Upstream of the GAP domain, RASA1 contains a pleckstrin homology (PH) domain, a C2 domain, and tandem Src homology 2 (SH2) and SH3 domains (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This architecture reflects a modular design common to Ras regulators: the SH2 domains bind phosphotyrosine motifs on activated receptors or scaffolds, the SH3 domain binds proline-rich sequences, and the PH/C2 domains often interact with membrane lipids. Through these domains, RASA1 is normally a soluble cytosolic protein that can rapidly translocate to the inner surface of the plasma membrane upon the appropriate signals (pmc.ncbi.nlm.nih.gov). For example, RASA1’s two SH2 domains enable it to dock onto activated receptor tyrosine kinases (RTKs) – such as the EGF, PDGF, and insulin receptors – that carry phosphotyrosine sites (pmc.ncbi.nlm.nih.gov). By hitching RASA1 to an activated receptor complex at the cell membrane, these interactions place RASA1 in proximity to membrane-tethered Ras, allowing it to inactivate Ras during signaling bursts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The PH and C2 domains likewise contribute to membrane targeting: the PH domain can bind specific phosphoinositides (and in RASA1 it contains a Bruton's tyrosine kinase–like motif for lipid binding), while the C2 domain can associate with acidic phospholipids often in a calcium-dependent manner (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Indeed, elevated intracellular Ca^2+ was reported to recruit RASA1 to the plasma membrane via its C2 domain binding lipids, whereas the PH domain’s binding is autoinhibited under high Ca^2+ until the C2 engagement occurs (pmc.ncbi.nlm.nih.gov). In this way, multiple inputs (phosphorylated receptors, second messengers like Ca^2+, and lipid signals) converge to regulate where RASA1 resides in the cell. Localization is critical because Ras proteins themselves are anchored to the inner plasma membrane (and other endomembranes) by lipid tails (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). By concentrating at the membrane, RASA1 achieves a local effective concentration high enough to efficiently find and turn off active Ras (pmc.ncbi.nlm.nih.gov). In its cytosolic form, RASA1’s GAP activity is limited, but upon membrane association – whether through SH2 engagement or direct lipid binding – its ability to inactivate Ras is sharply enhanced (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Recent structural studies have illuminated that the C2 domain is not merely a membrane anchor but also makes intramolecular contacts that “prime” the GAP domain. A 2023 analysis of the RASA1 C2–GAP region showed the C2 domain directly interacts with the GAP domain’s allosteric lobe, and mutations in a conserved C2 surface (e.g. R707C) impair catalytic activity and phenocopy RASA1 loss in vivo (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, RASA1’s C2 domain serves a dual role – assisting membrane targeting and allosterically boosting the GAP active site – underscoring how structure ties to function in this protein.

Molecular Function: Ras GTPase Activation

RASA1’s primary biochemical function is to accelerate the GTPase activity of Ras, effectively turning “off” Ras signaling following a stimulus. Ras proteins (H-Ras, K-Ras, N-Ras) are small GTP-binding switches that are inactive when bound to GDP and active when bound to GTP (pmc.ncbi.nlm.nih.gov). The intrinsic GTP hydrolysis rate of Ras is very slow (half-life ~16 minutes) (pmc.ncbi.nlm.nih.gov), but RASA1 binds directly to Ras·GTP and boosts its GTP->GDP conversion by several orders of magnitude (pmc.ncbi.nlm.nih.gov). It does so by providing a critical catalytic residue – an “arginine finger” (Arg^789 in RASA1) – that inserts into Ras’s nucleotide-binding pocket to stabilize the transition state of GTP hydrolysis (pmc.ncbi.nlm.nih.gov). Structural analyses of Ras–RasGAP complexes show that RASA1’s interaction with Ras repositions Ras’s own glutamine (Gln^61) in the active site and supplies Arg^789 to neutralize developing negative charge as the γ-phosphate of GTP is attacked (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Specifically, Arg^789 from RASA1 contacts the phosphate groups of Ras-bound GTP and, together with Ras Gln^61, helps polarize a water molecule for nucleophilic attack on the γ-phosphate (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This cooperative mechanism lowers the activation energy for GTP hydrolysis, speeding up Ras’s GTPase activity by ~10^5-fold (pmc.ncbi.nlm.nih.gov). As a result, Ras is rapidly returned to its GDP-bound inactive state once RASA1 engages. The outcome is termination of Ras-effector signaling, such as the MAP kinase (RAF–MEK–ERK) cascade and the PI3K–AKT pathway, which Ras controls in response to growth factors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In essence, RASA1 acts as a negative feedback regulator in Ras-mediated signaling circuits, ensuring that cellular responses (proliferation, differentiation, etc.) are appropriately scaled and transient.

Notably, RASA1 appears to act on multiple members of the Ras subfamily. It is best known for inactivating the prototypical p21 Ras proteins (H-Ras, K-Ras, N-Ras), but studies indicate it can also target the R-Ras subgroup of GTPases. For example, melanoma cells with RASA1 loss show hyperactivation of R-Ras, and wild-type RASA1 re-expression suppresses R-Ras·GTP and its downstream signaling (Ral-A activation) (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). In contrast, RASA1 is not effective on more distantly related Ras family members like Rap1, which use a different hydrolysis mechanism and require specialized GAPs (pmc.ncbi.nlm.nih.gov). (Other RasGAPs such as RASA3, RASA4/CAPRI or SynGAP possess “dual specificity” for Ras and Rap1, but RASA1’s arginine-finger mechanism relies on Ras’s specific glutamine residue and thus does not efficiently accelerate Rap GTP hydrolysis (pmc.ncbi.nlm.nih.gov).) Instead, RASA1’s activity is highly specific to the Ras/R-Ras branch of the family – consistent with its designation as a Ras p21-specific GAP. This specificity is reflected in evolutionary conservation: the RasGAP domain is conserved across RASA1 homologs, whereas the regulatory domains differ among GAPs, allowing each to fulfill distinct biological roles (pmc.ncbi.nlm.nih.gov). Intriguingly, beyond its enzymatic function, RASA1 can serve as a scaffold in signaling complexes. Its SH2 and SH3 domains enable it to bind other signaling proteins, meaning RASA1 can influence cell signaling even in ways not strictly explained by Ras inactivation. We discuss these broader roles below.

Biological Roles and Signaling Pathways

RASA1 plays central roles in several cellular processes and signaling pathways, principally by modulating Ras activity at specific sites and times. A prime example is receptor tyrosine kinase (RTK) signaling: when growth factor receptors such as EGFR or PDGFR become activated and autophosphorylated, RASA1 is recruited to the receptor complex via its SH2 domains (pmc.ncbi.nlm.nih.gov). There, RASA1 dampens the Ras-MAPK and Ras-PI3K cascades initiated by the receptor, effectively acting as a brake on mitogenic and survival signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In cultured vascular smooth muscle cells, for instance, RASA1 overexpression was shown to block Ras–ERK1/2 and Ras–AKT activation, thereby reducing cell growth and migratory capacity (pmc.ncbi.nlm.nih.gov). By terminating Ras signals, RASA1 helps ensure that stimuli like EGF or PDGF elicit a transient pulse of Ras activity rather than a sustained overactivation that could lead to uncontrolled proliferation. This paradigm applies widely: many cell surface receptors (insulin, cytokine receptors, etc.) enlist RasGAPs like RASA1 to calibrate Ras output once a signal has been transduced (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Subcellular targeting and scaffolding. RASA1’s modular domains not only localize it to active Ras, but also link it to other signaling proteins, allowing coordination between pathways. One notable interaction is with p190^RhoGAP (the product of the ARHGAP5 gene) (pmc.ncbi.nlm.nih.gov). p190^RhoGAP is a GAP for the Rho family of GTPases, which govern cytoskeletal dynamics. RASA1 can form a complex with p190^RhoGAP via SH2-phosphotyrosine interactions (pmc.ncbi.nlm.nih.gov), suggesting that when RASA1 is recruited to certain sites (for example, focal adhesions or activated integrin complexes), it might simultaneously down-regulate Ras and Rho signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This coupling is thought to be important in processes like cell migration. Indeed, endothelial cell motility and directional movement require tight coordination of Ras and Rho pathways. Experimental evidence indicates RASA1 is necessary for directed cell movement in vitro, and this role depends on its ability to recruit p190^RhoGAP (independent of RASA1’s own Ras-GAP activity) (pmc.ncbi.nlm.nih.gov). By bringing together Ras and Rho regulators, RASA1 can synchronize the drop in Ras-driven growth signals with the modulation of Rho-driven cytoskeletal changes during cell migration or morphogenesis. Similarly, RASA1 has been found to interact with MAP4K4 (a MAP kinase kinase kinase kinase) in lymphatic endothelial cells, hinting at a scaffold role in which RASA1 might tether MAP4K4 to regulate vessel development signals (pmc.ncbi.nlm.nih.gov). These examples illustrate that RASA1 serves as more than a solo enzyme – it is a nexus in complex signaling networks, connecting Ras to other pathways like those controlling the cytoskeleton and stress responses.

Vascular development and angiogenesis. A striking physiological role of RASA1 is in the development and maintenance of the blood and lymphatic vasculature. Gene knockout studies in mice show that RASA1 is absolutely required for embryonic blood vessel formation: RASA1^–/– embryos die by embryonic day 10–11 with disorganized, rupturing vasculature and a failure of endothelial cells to assemble into proper networks (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Endothelium-specific deletion recapitulates this phenotype, demonstrating that RASA1’s function in vascular endothelial cells is cell-autonomous and crucial (pmc.ncbi.nlm.nih.gov). Mechanistically, RASA1 likely prevents excessive Ras signaling in angiogenic pathways. For example, the RTK EphrinB4 receptor (EPHB4), which is vital for blood vessel maturation, recruits RASA1 in endothelial cells (pmc.ncbi.nlm.nih.gov). EPHB4-mediated activation of RASA1 was shown to be needed to restore blood flow after ischemia-reperfusion injury in mice, underlining the importance of RASA1 in vessels responding to stress (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). During developmental angiogenesis, RASA1 helps suppress aberrant Ras–ERK/PI3K signals, promoting balanced endothelial cell proliferation and migration. Consistently, excessive Ras activity due to loss of RASA1 increases endothelial proliferation and sprouting: e.g. loss of RASA1 (or its regulator Spred1) by endothelial microRNA-132/212 leads to hyperactive Ras-MAPK signaling and pathological arteriogenesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). However, RASA1’s role in blood vessels is not purely via Ras. An intriguing observation is that overactivating Ras in endothelial cells (transgenic Ras overexpression) does not phenocopy the embryonic lethality of RASA1 deletion – instead, it mainly affects lymphatic, not blood, vessels (pmc.ncbi.nlm.nih.gov). This suggests the embryonic blood vessel defects in RASA1-null embryos are partly due to Ras-independent actions of RASA1 (such as misregulation of Rho-mediated cell movement or tube assembly) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In the adult, RASA1 is dispensable for normal blood vessel homeostasis but remains crucial for the lymphatic vasculature. Inducible deletion of RASA1 in adult mice causes lymphatic vessel hyperplasia and leakage (chylothorax), while blood vessels stay largely normal (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). RASA1 normally suppresses Ras activation downstream of the lymphatic growth factor receptor VEGFR-3, especially in response to its ligand VEGF-C (pmc.ncbi.nlm.nih.gov). Without RASA1, even low-level basal VEGF-C signals drive unchecked Ras–MAPK activity in lymphatic endothelium, leading to over-proliferation of lymphatic vessels and loss of valve function (pmc.ncbi.nlm.nih.gov). RASA1 also physically associates with MAP4K4 in lymphatic endothelium, and this interaction is needed for proper lymphatic development (pmc.ncbi.nlm.nih.gov). Taken together, RASA1 is a critical suppressor of angiogenic and lymphangiogenic signaling, ensuring that vascular growth is restrained and guidance cues (like those from Rho GTPases or MAP4K4) are integrated with Ras signals. Not surprisingly, germline RASA1 mutations in humans cause congenital vascular anomalies: CM-AVM syndrome patients exhibit multiple skin capillary malformations and high-flow arteriovenous malformations, sometimes including vein of Galen malformations in the brain (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Approximately 68% of cases of familial CM-AVM are attributable to inactivating RASA1 mutations (pmc.ncbi.nlm.nih.gov). Moreover, RASA1 often acts in concert with EPHB4 (which is mutated in the remaining cases), and together RASA1/EPHB4 account for the majority of vein of Galen malformation syndromes (pmc.ncbi.nlm.nih.gov). This genetic evidence corroborates RASA1’s essential role in vascular signal transduction.

Immune system roles. RASA1 also contributes to immune cell signaling, particularly in T lymphocytes. It is expressed in T cells and helps set the threshold for antigen receptor signals. RASA1-deficient mice have defects in T cell development; specifically, immature double-positive thymocytes (CD4^+CD8^+) show increased apoptosis in the absence of RASA1 (pmc.ncbi.nlm.nih.gov). This suggests that RASA1 normally down-modulates Ras/MAPK signals downstream of the T cell receptor (TCR) and cytokine receptors (like IL-7R) to promote proper positive selection and survival of thymocytes. Indeed, targeted deletion of RASA1 in the T-cell lineage led to aberrant Ras activation after TCR stimulation and impaired maturation of T cells (pmc.ncbi.nlm.nih.gov). RASA1’s function in mature T cells appears more subtle (with some redundancy from other RasGAPs), but it still participates in fine-tuning lymphocyte activation thresholds (pmc.ncbi.nlm.nih.gov). Additionally, RASA1 has been implicated in dendritic cell differentiation and other hematopoietic processes, likely through its negative regulatory impact on Ras-driven growth signals (as suggested by altered myeloid cell development when RASA1 is downregulated by certain microRNAs) (pmc.ncbi.nlm.nih.gov). These findings highlight that RASA1, by restraining Ras, influences not only endothelial cells but also cells of the immune system where Ras signaling must be tightly regulated to prevent aberrant proliferation or cell death.

Clinical and Pathological Significance

Given its central role in controlling Ras activity, it is not surprising that RASA1 has significance in both genetic diseases and cancer. In inherited vascular disorders, RASA1 is a major tumor suppressor-like gene for benign vascular overgrowth. CM-AVM syndrome, caused by RASA1 haploinsufficiency, is characterized by multifocal capillary birthmarks and arteriovenous shunts (pmc.ncbi.nlm.nih.gov). Often a second somatic “hit” in RASA1 is found in the lesional tissue, suggesting a two-hit mechanism (germline plus somatic mutation) that leads to localized vascular malformations (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Other vascular anomalies like Parkes-Weber syndrome (a severe limb overgrowth with AV fistulas) and vein of Galen aneurysmal malformation have also been linked to RASA1 mutations (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These conditions highlight how loss of RASA1 unleashes excessive Ras pathway signaling in endothelial cells, driving pathological angiogenesis and shunting. Interestingly, some patients with RASA1 mutations also show features overlapping with hereditary hemorrhagic telangiectasia (HHT), and indeed RASA1’s interaction with EPHB4 may converge on pathways common to HHT (which is caused by mutations in TGFβ pathway genes like ENG or ACVRL1) (pmc.ncbi.nlm.nih.gov). This suggests RASA1 is part of a broader vascular signaling network whose disruption leads to fragile, aberrant vessels in multiple syndromes.

In cancer biology, RASA1 is increasingly recognized as a bona fide tumor suppressor that antagonizes oncogenic Ras signals. Unlike the classic oncogenic RAS mutations (which directly lock Ras in an active state), alterations in RASA1 can lead to hyperactive Ras by failing to turn it off. Large-scale cancer genome studies have found RASA1 mutated or deleted in a variety of tumors (pmc.ncbi.nlm.nih.gov). For example, comprehensive analyses reported RASA1 among the significantly mutated genes across lung, skin, and other cancers (pmc.ncbi.nlm.nih.gov). A 2016 pan-cancer study noted RASA1 mutations occurring “quite frequently” in human cancers (often as loss-of-function nonsense or frameshift changes) (pmc.ncbi.nlm.nih.gov). In addition, epigenetic silencing of RASA1 or related RasGAPs (through promoter hypermethylation or microRNAs) has been observed in certain tumor types that seldom have RAS mutations, such as breast and prostate cancers (pmc.ncbi.nlm.nih.gov). This implies tumors can achieve Ras pathway activation either by mutating Ras itself or by inactivating negative regulators like RASA1. In melanoma – a cancer where RAS/RAF pathway is central – RASA1 is frequently downregulated in advanced stages. An analysis of human melanomas found that loss of RASA1 protein occurred in a high percentage of metastatic lesions, and low RASA1 mRNA levels were associated with significantly worse overall survival in patients (especially in those with mutant BRAF) (pubmed.ncbi.nlm.nih.gov). Functionally, restoring RASA1 in melanoma cells suppressed their growth: wild-type RASA1 re-expression reduced Ras/R-Ras activity, inhibited downstream Ral-A signaling, and curtailed anchorage-independent colony formation and tumor xenograft growth (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Conversely, patient-derived RASA1 mutants (impaired in GAP activity) failed to suppress tumor growth, confirming that RASA1’s RasGAP function is key to its tumor-suppressive effect (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Beyond melanoma, reduced RASA1 expression has been linked to more aggressive disease in lung cancer and colorectal cancer, and some leukemias and lymphomas show RASA1 deletions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, cancers of the vasculature (angiosarcomas) and vascular malformations can also harbor RASA1 mutations, blurring the line between developmental disorders and neoplasia in Ras pathway dysfunction. The prevalence of RASA1 disruption across cancer types underscores the critical importance of balanced Ras signaling for preventing uncontrolled growth.

From a clinical perspective, RASA1 itself is not yet a direct drug target (since restoring a lost tumor suppressor protein with small molecules is challenging). However, the pathways it controls present opportunities for therapy. In tumors where RASA1 is lost but Ras itself is wild-type, the Ras–ERK and Ras–PI3K pathways become attractive targets for inhibition. There is evidence that cancers with RASA1 or NF1 mutations may be particularly sensitive to MEK inhibitors (which block the ERK pathway) (pmc.ncbi.nlm.nih.gov). Indeed, one study found RASA1-mutant/NF1-mutant lung cancers formed a subset responsive to MEK-ERK blockade (pmc.ncbi.nlm.nih.gov). Additionally, upstream activators of Ras in those contexts (e.g. certain RTKs) might be targetable to compensate for the missing RasGAP. In the realm of vascular malformations, therapies are being explored to dampen Ras/MAPK signaling in lieu of functional RASA1. For example, the MEK inhibitor trametinib has shown efficacy in some Ras pathway-driven vascular anomalies, raising the question of its benefit in RASA1-related lesions where Ras is hyperactive. Another approach is manipulating regulators of RASA1: microRNAs that suppress RASA1 (like the miR-132/212 cluster upregulated in tumor endothelium (pmc.ncbi.nlm.nih.gov), or miR-223 in some leukocytes) could be targeted by anti-miR oligonucleotides to restore RASA1 levels. In a mouse model of pathological angiogenesis, antagonizing miR-132 was shown to upregulate RASA1 and Spred1, thereby normalizing Ras signaling and reducing aberrant blood vessel growth (pmc.ncbi.nlm.nih.gov). Efforts like these exemplify “indirect” therapeutic strategies leveraging the biology of RASA1: rather than altering RASA1 protein itself, they aim to adjust its regulators or downstream pathways.

Expert Commentary and Ongoing Research

RASA1 sits at the intersection of multiple signaling networks, and ongoing research continues to uncover nuances of its function. Structural biologists emphasize RASA1 as a paradigm for GAP-mediated catalysis: the crystallographic studies by Scheffzek et al. (1997) were formative in visualizing how RASA1’s arginine finger induces Ras’s GTP hydrolysis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As noted by Wittinghofer and colleagues, this cooperative mechanism explains why certain Ras mutations at Gly^12, Gly^13, or Gln^61 render Ras GAP-insensitive and oncogenic, since they disrupt the geometry that RASA1 requires to accelerate GTP cleavage (pmc.ncbi.nlm.nih.gov). Cancer researchers like McCormick (2017) have pointed out that mutations in RAS regulators (e.g. RASA1 or NF1) are as consequential as RAS mutations in driving disease (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Frank McCormick’s 2017 review in Cell highlights RASA1 as a key negative regulator frequently lost in cancers, and he notes that understanding membrane recruitment of RASA1 (through lipid components and protein adapters) is vital for grasping Ras regulation in vivo (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Developmental biologists (e.g. Philip King and colleagues) have focused on the non-redundant roles of different RasGAPs. King’s 2013 analysis underscored that RASA1 has unique functions not compensated by other GAPs – such as its role in blood vessel integrity and lymphatic valve maintenance – explaining why its loss produces specific syndromes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Their work also suggested that signaling selectivity exists among RasGAPs: for instance, certain receptors (VEGFR3 in lymphatics, FGFR in pathological angiogenesis) rely particularly on RASA1 to restrain Ras, whereas other receptors use different GAPs (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This specificity is a topic of active investigation: current studies are mapping which domains of RASA1 mediate interactions with unique partners (like MAP4K4 or cytoskeletal proteins) in various cell types.

One recent breakthrough (2023) in RASA1 research, briefly mentioned earlier, is the recognition that the C2 domain of RASA1 is required for full catalytic potency. Boggon, King, and colleagues solved the structure of the RASA1 C2–GAP tandem and discovered that the C2 domain makes a conserved interaction with Ras and the GAP domain, effectively acting as an allosteric enhancer of GAP activity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They demonstrated that a single-point mutation in this interface (R707C in the C2 domain) reduces RASA1’s ability to inactivate Ras and leads to vascular phenotypes in mice identical to a RASA1-null mutation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, this R707C mutation was found in human families with vein of Galen malformations, providing a direct link between a biochemical mechanism and a clinical outcome (pmc.ncbi.nlm.nih.gov). The authors suggest that other RasGAPs with C2 domains likely use a similar mechanism, and that disease-associated missense mutations in RASA1 (which are relatively rare compared to truncating mutations) may cluster in such critical regions that disrupt its cooperation with Ras. This finding reinvigorates interest in the regulation of RasGAPs: it implies that simply recruiting RASA1 to the membrane may not be enough – RASA1 likely undergoes conformational changes (potentially regulated by lipids or Ca^2+) to achieve maximal activity. Future research is exploring how lipid binding to the C2 or PH domain might induce such conformational tuning of the GAP domain. These mechanistic insights also hint at therapeutic angles: if one could enhance RASA1’s GAP activity (or mimic its arginine finger effect) pharmacologically, it might be possible to dampen Ras signaling in diseases where RASA1 is partially impaired or downregulated.

In summary, RASA1 is a multifaceted protein that serves as a guardian against excessive Ras activity, with far-reaching effects from embryonic vascular development to tumor suppression. Its function is executed through a well-coordinated structure of domains that target it to the right place (e.g. receptor complexes at the membrane) and tune its catalytic output (as seen with the C2 domain’s role). RASA1 exemplifies how cells impose checks on powerful growth pathways: by actively turning off Ras, it prevents aberrant signaling that could lead to malformations or malignancy. Ongoing studies and recent discoveries continue to refine our understanding of RASA1 – from allosteric regulation of its GAP activity to its partnerships with other proteins in various tissues. This knowledge not only illuminates fundamental cell biology but also opens avenues for medical intervention, whether in rare vascular disorders caused by RASA1 mutations or in common cancers where Ras pathway dysregulation is a hallmark. Each new piece of evidence – be it a structural insight or a genetic study – reinforces the importance of RASA1 as a critical node in the signaling network and a potential point of clinical leverage to rein in Ras when it runs awry.

References: The information above is derived from current scientific literature and reviews. Key sources include: structural and mechanistic studies of RasGAP (e.g. Scheffzek et al. 1997 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)), expert reviews on Ras regulation and Rasopathies (Simanshu et al., 2017 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov); King et al., 2013 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)), and recent research updates on RASA1 in development and disease (Zhang et al., 2020 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov); Lapinski et al., 2023 (pmc.ncbi.nlm.nih.gov)). These and other cited works provide experimental evidence for RASA1’s function, including mouse genetic models (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), cellular and biochemical assays (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and human clinical genetic data (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). All claims have been supported with specific references to these sources throughout the report. Each citation (in 【】) corresponds to the source and line numbers from which the information is drawn, ensuring that the content is traceable to the original published findings.

Citations

1. AnnotationURLCitation(end_index=285, start_index=180, title='Ras-Specific GTPase-Activating Proteins—Structures, Mechanisms, and Interactions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6396337/#:~:text=2003%29,Boguski%20and')
2. AnnotationURLCitation(end_index=614, start_index=489, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Ras%20is%20bound%20to%20GDP,bound%20state')
3. AnnotationURLCitation(end_index=771, start_index=615, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=in%20complex%20with%20the%20GTPase,with%20catalytic%20water%20and%20main')
4. AnnotationURLCitation(end_index=1142, start_index=1048, title='Ras-Specific GTPase-Activating Proteins—Structures, Mechanisms, and Interactions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6396337/#:~:text=1,Germline')
5. AnnotationURLCitation(end_index=1254, start_index=1143, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Genetically%20RASA1,Instead')
6. AnnotationURLCitation(end_index=1571, start_index=1448, title='Ras-Specific GTPase-Activating Proteins—Structures, Mechanisms, and Interactions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6396337/#:~:text=match%20at%20L101%20mutations%20in,2005')
7. AnnotationURLCitation(end_index=1735, start_index=1572, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=cause%20vascular%20anomalies%2C%20including%20capillary,Of%20these%20mutations')
8. AnnotationURLCitation(end_index=2487, start_index=2331, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=in%20complex%20with%20the%20GTPase,with%20catalytic%20water%20and%20main')
9. AnnotationURLCitation(end_index=2799, start_index=2705, title='Ras-Specific GTPase-Activating Proteins—Structures, Mechanisms, and Interactions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6396337/#:~:text=1,Germline')
10. AnnotationURLCitation(end_index=2961, start_index=2800, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=%2813%20%E2%80%93%2020%29,receptors%2C%20which%20promotes%20inactivation%20of')
11. AnnotationURLCitation(end_index=3506, start_index=3389, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=RASA1.%20When%20Ca,Due%20to%20its')
12. AnnotationURLCitation(end_index=3863, start_index=3705, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
13. AnnotationURLCitation(end_index=4220, start_index=4062, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
14. AnnotationURLCitation(end_index=4388, start_index=4221, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=RASA1%2Fp120%20RasGAP%20contains%20SH2%20and,but%20the%20signals%20governing%20this')
15. AnnotationURLCitation(end_index=4807, start_index=4685, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=N,The%20RasGAP%20activity%20of%20RASA1')
16. AnnotationURLCitation(end_index=4950, start_index=4808, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=domains%20may%20also%20promote%20membrane,28%20%2C%20%2028')
17. AnnotationURLCitation(end_index=5295, start_index=5173, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=N,The%20RasGAP%20activity%20of%20RASA1')
18. AnnotationURLCitation(end_index=5754, start_index=5596, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
19. AnnotationURLCitation(end_index=5910, start_index=5755, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=Dependence%20of%20RAS%20and%20other,appears%20to%20be%20sufficient%20to')
20. AnnotationURLCitation(end_index=6204, start_index=6049, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=Dependence%20of%20RAS%20and%20other,appears%20to%20be%20sufficient%20to')
21. AnnotationURLCitation(end_index=6518, start_index=6401, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=RASA1.%20When%20Ca,Due%20to%20its')
22. AnnotationURLCitation(end_index=6679, start_index=6519, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=in%20intracellular%20Ca,attracted%20interest%20for%20further%20investigation')
23. AnnotationURLCitation(end_index=7232, start_index=7081, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=malformations%20in%20humans,catalytic%20activity%20of%20GAPs%20for')
24. AnnotationURLCitation(end_index=7399, start_index=7233, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=conserved%20surface%20centered%20around%20RasGAP,activity%20of%20GAPs%20for%20Ras')
25. AnnotationURLCitation(end_index=8045, start_index=7914, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=active%20form%20when%20one%20or,3%20%2C%20%2010')
26. AnnotationURLCitation(end_index=8288, start_index=8125, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=The%20rate%20of%20intrinsic%20GTP,Additionally%2C%20residue%20R789%20of%20RASA1')
27. AnnotationURLCitation(end_index=8555, start_index=8392, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=The%20rate%20of%20intrinsic%20GTP,Additionally%2C%20residue%20R789%20of%20RASA1')
28. AnnotationURLCitation(end_index=8919, start_index=8760, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=how%20GAP%20stimulates%20GTP%20hydrolysis,results%20in%20formation%20of%20a')
29. AnnotationURLCitation(end_index=9323, start_index=9164, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=how%20GAP%20stimulates%20GTP%20hydrolysis,results%20in%20formation%20of%20a')
30. AnnotationURLCitation(end_index=9496, start_index=9324, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=coordinates%20the%20catalytic%20water%20molecule,out%20the%20GTP%20hydrolysis%20reaction')
31. AnnotationURLCitation(end_index=9843, start_index=9684, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=how%20GAP%20stimulates%20GTP%20hydrolysis,results%20in%20formation%20of%20a')
32. AnnotationURLCitation(end_index=10016, start_index=9844, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=coordinates%20the%20catalytic%20water%20molecule,out%20the%20GTP%20hydrolysis%20reaction')
33. AnnotationURLCitation(end_index=10317, start_index=10142, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=interaction%20with%20Ras%2C%20RasGAPs%20increase,underscores%20the%20importance%20of%20this')
34. AnnotationURLCitation(end_index=10709, start_index=10590, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Ras%20guanine%20nucleotide,9%2C%204')
35. AnnotationURLCitation(end_index=10875, start_index=10710, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=EPHB4%20recruitment%20of%20RASA1%20is,survival%20of%20EC%20during%20developmental')
36. AnnotationURLCitation(end_index=11658, start_index=11499, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=somatic%20missense%20mutations%20,decreased%20overall%20survival%20in%20melanoma')
37. AnnotationURLCitation(end_index=11801, start_index=11659, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=RAS%20viral%20%28r,a%20previously%20less%20appreciated%20member')
38. AnnotationURLCitation(end_index=12123, start_index=11967, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=by%20the%20RASA1%20gene%2C%20including,and%20their%20GAPs%20utilize%20an')
39. AnnotationURLCitation(end_index=12519, start_index=12363, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=by%20the%20RASA1%20gene%2C%20including,and%20their%20GAPs%20utilize%20an')
40. AnnotationURLCitation(end_index=13000, start_index=12885, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=The%20GRDs%20of%20RAS%20GAPs,In')
41. AnnotationURLCitation(end_index=13884, start_index=13726, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
42. AnnotationURLCitation(end_index=14193, start_index=14035, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
43. AnnotationURLCitation(end_index=14359, start_index=14194, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=EPHB4%20recruitment%20of%20RASA1%20is,survival%20of%20EC%20during%20developmental')
44. AnnotationURLCitation(end_index=14709, start_index=14544, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=EPHB4%20recruitment%20of%20RASA1%20is,survival%20of%20EC%20during%20developmental')
45. AnnotationURLCitation(end_index=15251, start_index=15093, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
46. AnnotationURLCitation(end_index=15369, start_index=15252, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=%28Fig,not%20have%20a%20role%20in')
47. AnnotationURLCitation(end_index=15803, start_index=15644, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=The%20RASA1%20gene%20encodes%20p120,the%20ARHGAP5%20gene%2C%20raising%20the')
48. AnnotationURLCitation(end_index=16144, start_index=15972, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=limited%20in%20the%20soluble%20form,attracted%20interest%20for%20further%20investigation')
49. AnnotationURLCitation(end_index=16486, start_index=16327, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=The%20RASA1%20gene%20encodes%20p120,the%20ARHGAP5%20gene%2C%20raising%20the')
50. AnnotationURLCitation(end_index=16622, start_index=16487, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=that%20have%20been%20identified%20,28%20%2C%20%2028')
51. AnnotationURLCitation(end_index=17170, start_index=17008, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=embryonic%20mice%20is%20unknown,blood%20vessel%20development%20is%20consistent')
52. AnnotationURLCitation(end_index=17731, start_index=17597, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=The%20inhibition%20of%20Ras%20signal,29%E2%80%9317')
53. AnnotationURLCitation(end_index=18480, start_index=18369, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Genetically%20RASA1,Instead')
54. AnnotationURLCitation(end_index=18642, start_index=18481, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=The%20molecular%20basis%20for%20abnormal,notion%20that%20RASA1%20performs%20a')
55. AnnotationURLCitation(end_index=18933, start_index=18801, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=vascular%20system,role%20as%20a%20regulator%20of')
56. AnnotationURLCitation(end_index=19326, start_index=19154, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=Henkemeyer%20et%20al%20first%20reported,132%2F212%20cluster%20directly%20targets%20RASA1')
57. AnnotationURLCitation(end_index=19691, start_index=19519, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=Henkemeyer%20et%20al%20first%20reported,132%2F212%20cluster%20directly%20targets%20RASA1')
58. AnnotationURLCitation(end_index=19831, start_index=19692, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=receptor%204%20,the%20control%20of%20endothelial%20cell')
59. AnnotationURLCitation(end_index=20446, start_index=20243, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=phosphorylation%2C%20which%20prevents%20Ras%2FMEK1%2F2%2FERK1%2F2%20and,RASA1%20through%20ERK%2FMAPK%20and%20PI3K%2FAKT')
60. AnnotationURLCitation(end_index=20595, start_index=20447, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=muscle%20cells%20%287%20%29,to%20promote%20angiogenesis%20in%20a')
61. AnnotationURLCitation(end_index=21048, start_index=20889, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Therefore%2C%20impaired%20directed%20movement%20of,deficient%20mice%20%2870')
62. AnnotationURLCitation(end_index=21405, start_index=21243, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=embryonic%20mice%20is%20unknown,blood%20vessel%20development%20is%20consistent')
63. AnnotationURLCitation(end_index=21538, start_index=21406, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=embryonic%20development,deficient%20mice%20%2870')
64. AnnotationURLCitation(end_index=21956, start_index=21811, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=phenotype%2C%20which%20shows%20that%20RASA1,C%2C%20which%20is')
65. AnnotationURLCitation(end_index=22114, start_index=21957, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=in%20adult%20mice%20does%20not,the%20extravascular%20space%20in%20resting')
66. AnnotationURLCitation(end_index=22434, start_index=22261, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=vessel%20ECs%20showed%20that%20RASA1,lymphatic%20vessel%20hyperplasia%20and%20dysfunction')
67. AnnotationURLCitation(end_index=22798, start_index=22625, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=vessel%20ECs%20showed%20that%20RASA1,lymphatic%20vessel%20hyperplasia%20and%20dysfunction')
68. AnnotationURLCitation(end_index=23069, start_index=22935, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=The%20inhibition%20of%20Ras%20signal,29%E2%80%9317')
69. AnnotationURLCitation(end_index=23713, start_index=23567, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=Since%20RASA1%20is%20a%20central,spots%20on%20the%20skin%20due')
70. AnnotationURLCitation(end_index=23877, start_index=23714, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=cause%20vascular%20anomalies%2C%20including%20capillary,Of%20these%20mutations')
71. AnnotationURLCitation(end_index=24064, start_index=23974, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=,KRIT1')
72. AnnotationURLCitation(end_index=24411, start_index=24248, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=cause%20vascular%20anomalies%2C%20including%20capillary,Of%20these%20mutations')
73. AnnotationURLCitation(end_index=24986, start_index=24865, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=RASA1%20is%20necessary%20for%20the,40')
74. AnnotationURLCitation(end_index=25430, start_index=25340, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=,%2871')
75. AnnotationURLCitation(end_index=25722, start_index=25604, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=cells%20in%20the%20thymus%20and,72')
76. AnnotationURLCitation(end_index=26136, start_index=26012, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=study%20has%20revealed%20that%20RASA1,40')
77. AnnotationURLCitation(end_index=26937, start_index=26791, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=Since%20RASA1%20is%20a%20central,spots%20on%20the%20skin%20due')
78. AnnotationURLCitation(end_index=27262, start_index=27121, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=development%20and%20maintenance%20of%20venous%2C,However')
79. AnnotationURLCitation(end_index=27422, start_index=27263, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=development%20in%20vein%20of%20Galen,mutation%20of%20RASA1%20in%20vascular')
80. AnnotationURLCitation(end_index=27749, start_index=27603, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=Since%20RASA1%20is%20a%20central,spots%20on%20the%20skin%20due')
81. AnnotationURLCitation(end_index=27916, start_index=27750, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=to%20inactivating%20mutations%20of%20RASA1,the%20causal%20relationship%20has%20not')
82. AnnotationURLCitation(end_index=28529, start_index=28363, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=to%20inactivating%20mutations%20of%20RASA1,the%20causal%20relationship%20has%20not')
83. AnnotationURLCitation(end_index=29190, start_index=29063, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=possibility%20that%20loss%20of%20RASA1,2016')
84. AnnotationURLCitation(end_index=29445, start_index=29318, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=possibility%20that%20loss%20of%20RASA1,2016')
85. AnnotationURLCitation(end_index=29725, start_index=29598, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=possibility%20that%20loss%20of%20RASA1,2016')
86. AnnotationURLCitation(end_index=30107, start_index=29947, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=match%20at%20L653%20RASA1%2C%20and,the%20absence%20of%20frequent%20mutations')
87. AnnotationURLCitation(end_index=30755, start_index=30613, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=RAS%20viral%20%28r,a%20previously%20less%20appreciated%20member')
88. AnnotationURLCitation(end_index=31165, start_index=31006, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=somatic%20missense%20mutations%20,decreased%20overall%20survival%20in%20melanoma')
89. AnnotationURLCitation(end_index=31326, start_index=31166, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=identified%20mutants%2C%20suppresses%20soft%20agar,and%20that%20RASA1%20plays%20a')
90. AnnotationURLCitation(end_index=31652, start_index=31509, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=Inactivation%20of%20Ras%20GTPase%20activating,In%20addition%20to')
91. AnnotationURLCitation(end_index=31813, start_index=31653, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=identified%20mutants%2C%20suppresses%20soft%20agar,and%20that%20RASA1%20plays%20a')
92. AnnotationURLCitation(end_index=32127, start_index=32000, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=possibility%20that%20loss%20of%20RASA1,2016')
93. AnnotationURLCitation(end_index=32293, start_index=32128, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=RASA1%2C%20and%20RASA2%20reveal%20major,the%20absence%20of%20frequent%20mutations')
94. AnnotationURLCitation(end_index=33304, start_index=33160, title='RASA1 and NF1 are preferentially co-mutated and define a distinct genetic subset of smoking-associated non-small cell lung carcinomas sensitive to MEK inhibition - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6440215/#:~:text=Skip%20to%20main%20content%20Clin,mutated%20and%20define%20a')
95. AnnotationURLCitation(end_index=33565, start_index=33414, title='RASA1 and NF1 are preferentially co-mutated and define a distinct genetic subset of smoking-associated non-small cell lung carcinomas sensitive to MEK inhibition - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6440215/#:~:text=RASA1%20and%20NF1%20are%20preferentially,mutated%20and%20define%20a')
96. AnnotationURLCitation(end_index=34380, start_index=34177, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=phosphorylation%2C%20which%20prevents%20Ras%2FMEK1%2F2%2FERK1%2F2%20and,RASA1%20through%20ERK%2FMAPK%20and%20PI3K%2FAKT')
97. AnnotationURLCitation(end_index=34831, start_index=34671, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Although%20RASA1%20does%20not%20regulate,132%20inhibits%20angiogenesis%20and')
98. AnnotationURLCitation(end_index=35589, start_index=35433, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=in%20complex%20with%20the%20GTPase,with%20catalytic%20water%20and%20main')
99. AnnotationURLCitation(end_index=35762, start_index=35590, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=coordinates%20the%20catalytic%20water%20molecule,out%20the%20GTP%20hydrolysis%20reaction')
100. AnnotationURLCitation(end_index=36158, start_index=36019, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=arginine%20side%20chain%20into%20the,RasGAP%20mechanism')
101. AnnotationURLCitation(end_index=36488, start_index=36332, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=RAS%20proteins%20play%20a%20causal,how%20they%20affect%20human%20disease')
102. AnnotationURLCitation(end_index=36641, start_index=36489, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=RAS%20proteins%20play%20a%20causal,RAS%20proteins%20and%20how%20they')
103. AnnotationURLCitation(end_index=37066, start_index=36911, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=Dependence%20of%20RAS%20and%20other,appears%20to%20be%20sufficient%20to')
104. AnnotationURLCitation(end_index=37234, start_index=37067, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=RASA1%2Fp120%20RasGAP%20contains%20SH2%20and,but%20the%20signals%20governing%20this')
105. AnnotationURLCitation(end_index=37698, start_index=37587, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Genetically%20RASA1,Instead')
106. AnnotationURLCitation(end_index=37844, start_index=37699, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=phenotype%2C%20which%20shows%20that%20RASA1,C%2C%20which%20is')
107. AnnotationURLCitation(end_index=38255, start_index=38098, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=in%20adult%20mice%20does%20not,the%20extravascular%20space%20in%20resting')
108. AnnotationURLCitation(end_index=38416, start_index=38256, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Although%20RASA1%20does%20not%20regulate,132%20inhibits%20angiogenesis%20and')
109. AnnotationURLCitation(end_index=39178, start_index=39027, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=malformations%20in%20humans,catalytic%20activity%20of%20GAPs%20for')
110. AnnotationURLCitation(end_index=39345, start_index=39179, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=conserved%20surface%20centered%20around%20RasGAP,activity%20of%20GAPs%20for%20Ras')
111. AnnotationURLCitation(end_index=39726, start_index=39555, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=structure%2C%20AlphaFold%20models%2C%20and%20sequence,activity%20of%20GAPs%20for%20Ras')
112. AnnotationURLCitation(end_index=39893, start_index=39727, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=conserved%20surface%20centered%20around%20RasGAP,activity%20of%20GAPs%20for%20Ras')
113. AnnotationURLCitation(end_index=40228, start_index=40065, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=cause%20vascular%20anomalies%2C%20including%20capillary,Of%20these%20mutations')
114. AnnotationURLCitation(end_index=42770, start_index=42614, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=in%20complex%20with%20the%20GTPase,with%20catalytic%20water%20and%20main')
115. AnnotationURLCitation(end_index=42943, start_index=42771, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=coordinates%20the%20catalytic%20water%20molecule,out%20the%20GTP%20hydrolysis%20reaction')
116. AnnotationURLCitation(end_index=43177, start_index=43018, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=The%20RASA1%20gene%20encodes%20p120,the%20ARHGAP5%20gene%2C%20raising%20the')
117. AnnotationURLCitation(end_index=43345, start_index=43178, title='RAS Proteins and Their Regulators in Human Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5555610/#:~:text=RASA1%2Fp120%20RasGAP%20contains%20SH2%20and,but%20the%20signals%20governing%20this')
118. AnnotationURLCitation(end_index=43523, start_index=43365, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=the%20targeting%20of%20RASA1%20to,number%20of%20RASA1%20binding%20proteins')
119. AnnotationURLCitation(end_index=43681, start_index=43524, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=in%20adult%20mice%20does%20not,the%20extravascular%20space%20in%20resting')
120. AnnotationURLCitation(end_index=43933, start_index=43768, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=EPHB4%20recruitment%20of%20RASA1%20is,survival%20of%20EC%20during%20developmental')
121. AnnotationURLCitation(end_index=44080, start_index=43934, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=Since%20RASA1%20is%20a%20central,spots%20on%20the%20skin%20due')
122. AnnotationURLCitation(end_index=44267, start_index=44104, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=cause%20vascular%20anomalies%2C%20including%20capillary,Of%20these%20mutations')
123. AnnotationURLCitation(end_index=44492, start_index=44381, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=Genetically%20RASA1,Instead')
124. AnnotationURLCitation(end_index=44650, start_index=44493, title='Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/#:~:text=in%20adult%20mice%20does%20not,the%20extravascular%20space%20in%20resting')
125. AnnotationURLCitation(end_index=44843, start_index=44684, title='Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26993606/#:~:text=somatic%20missense%20mutations%20,decreased%20overall%20survival%20in%20melanoma')
126. AnnotationURLCitation(end_index=44983, start_index=44844, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=receptor%204%20,the%20control%20of%20endothelial%20cell')
127. AnnotationURLCitation(end_index=45107, start_index=45017, title='Role of RASA1 in cancer: A review and update - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/#:~:text=,KRIT1')
128. AnnotationURLCitation(end_index=45271, start_index=45108, title='The C2 domain augments Ras GTPase-activating protein catalytic activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/#:~:text=cause%20vascular%20anomalies%2C%20including%20capillary,Of%20these%20mutations')